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1.1. Mitochondria 
 
1.1.1. Mitochondrial structure and function 
Mitochondria are eukaryotic organelles responsible for several essential metabolic 
processes. They are involved in the cellular signaling, in programmed cell death, in heme 
and Fe/S clusters biogenesis, in the oxidation of pyruvate, in the Krebs cycle, in 
metabolism of amino acids, fatty acids, cholesterol, steroids and nucleotides (Scheffler, 
2008). However their most important function is to generate most of the cell‟s chemical 
energy in the form of adenosine triphosphate (ATP) by the process of aerobic respiration 
and the oxidative phosphorylation.  
Mitochondria are ellipsoidal organelles and have no fixed size, generally with a diameter 
ranging from 0.2 to 1 µm and a length of 3-4 µm. They contains two membranes that 
separate four distinct compartments, the outer membrane (OMM), the intermembrane 
space, inner membrane (IMM) and the matrix (Mcbride et al., 2006).  
 
Figure 1.1. A mitochondrion (http://biology.unm.edu/ccouncil/Biology_124/Summaries/Cell.html) 
There are some differences in phospholipid composition between the outer and inner 
membrane. The phospholipid: protein ratio is higher in the outer than in the inner 
membrane (Guérin, 1991) The inner membrane is enriched with cardiolipin whereas the 
outer membrane is enriched with phosphatidylinositol (Bottema and Parks, 1980; Daum, 
1985). The outer membrane has pore-forming proteins called porins which allow the outer 
membrane to be permeable to molecules of 10kDa or less. The inner membrane is not 
freely permeable and contains a series of specific carriers that allow connections between 
the mitochondrial and cytoplasmic metabolism (Guérin, 1991). The inner membrane is 
3 
 
highly folded into special structures called cristae in which most of the OXPHOS proteins 
are located (Griparic and Van der bliek, 2001). The organization in these special 
structures greatly increases the total surface area of the inner membrane, optimizing the 
energy production processes.  
Mitochondria are very dynamic organelles (Dimmer et al., 2002) and form a functional 
reticulum whose steady-state morphology is regulated by dynamic fission, fusion and 
motility events (Mcbride et al., 2006). It is thought that the balance between 
mitochondrial fission and fusion is essential in mitochondrial function and maintenance 
(Chen et al., 2003). By definition, mitochondria are able to express an integral genome 
and generate ATP coupled with electron transport. 
In the cell their distribution and morphology vary according to the cell‟s metabolic 
demand (Bereiter-Hahn, 1994; Warren and Wickne, 1996; Hermann and Shaw, 1998; 
Yaffe, 1999). Tissues with high energy demands such as hearth, brain and muscle, have a 
rich number of mitochondria and these tissues are more vulnerable to mitochondrial 
defects. 
Respect to other organelles, mitochondria have a peculiar characteristic: they posses their 
own genome, mitochondrial DNA or mtDNA and protein synthesis machinery. More than 
one copy of mtDNA is present in mitochondria and their number depends on the cellular 
conditions, environmental factors and in the case of multicellular organisms on the 
tissues.  
 
1.1.2. mtDNA 
Mitochondrial DNA in mammalian cells is circular double stranded DNA of 16.5Kb (fig.1). 
Mitochondrial DNA is not associated with histones but organized in a very compact 
structure called nucleoid, anchored to the inner membrane and stabilized by DNA-binding 
proteins different from the histones organizers on nuclear DNA (Satoh and Kuroiwa, 
1991). An average nucleoid in mammalian cells contains 5-7 genomes (Atkinson and 
Winge, 2009). Furthermore, mtDNA is replicated continuously in a process independent 
from nuclear genome replication, occurring in both mitotic and post-mitotic cells (Yu-Wai-
Man et al., 2011). Mammalian mtDNA encodes for only 13 proteins of total mitochondrial 
proteins as well as for 22 tRNA and 2 rRNA that are essential for the mitochondrial 
translation. The 13 mtDNA encoded polypeptides consist of seven subunits of complex I 
(ND1, ND2, ND3, ND4, ND4L, ND5, ND6), one subunit of complex III (CytB), three 
subunits of complex IV (COXI, COXII, COXIII) and two subunits of complex V (ATPase 5 
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and ATPase 6). The other mitochondrial proteins such as all subunits of complex II and 
the mitochondrial DNA polymerase (γ) are encoded by nuclear DNA and are imported into 
mitochondria through specialized import machineries (Baker et al., 2007; Neupert and 
Herrmann, 2007). This is possible thanks to a N-terminal target sequence for 
mitochondria which is processed when the proteins are traslocated (Hartl, 1989; Glick and 
Schatz, 1991; Neupert, 1997). 
 
Figure 1.2. Yeast and Human mtDNA maps. Each map is shown as two concentric circles corresponding to 
the two strands of the DNA helix. Note that the mutants used in yeast mtDNA analysis are shown opposite 
their corresponding structural genes. Green = exons and uninterrupted genes, red = tRNA genes, and yellow 
= URFs (unassigned reading frames). tRNA genes are shown by their amino acid abbreviations; ND genes 
code for subunits of NADH dehydrogenase. (Note that the human map is not drawn to the same scale as the 
yeast map.) From Inheritance of Organelle Genes, 1999, W. H. Freeman and Company 
 
Yeast mtDNA has a size ranging from 68Kb (short strain) to 86Kb (long strain). Unlike the 
human mtDNA, the yeast mitochondrial genome is less compact and contains both non 
coding and intronic regions. The yeast mtDNA encodes for 19 proteins: among these 
there are the subunits of complex III, Cob or CytB, and other three subunits of complex 
IV, Cox1p, Cox2p, Cox3p as in human. Moreover, in mtDNA are encoded three subunits of 
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ATP synthase complex ( Atp6, Atp8 and Atp9) so as the Var1p, a ribosomal mitochondrial 
protein (VAR1). The other 11 polypeptides, encoded in introns of 21S rRNA, COB and 
COX1 genes, consist of maturases, endonucleases and reverse transcriptases and in a 
protein of unknown function yet. In addition mtDNA whose genetic code is different 
respect to the universal code, encodes for 24 mitochondrial tRNAs, 2 rRNA and for an 
RNA belonging to RNAse P. In the short strains all these elements are present except for 
some non coding and intronic regions. 
 
1.2. Functions 
Among mitochondrial functions, the most important one is the conversion of energetic 
metabolic intermediates into H2O and CO2 coupled to ATP production. These substrates 
come from catabolic pathways that take place in mitochondria such as oxidative 
degradation of pyruvate, fatty acids and some aminoacids. 
 
1.2.1. Oxidation of pyruvate and fatty acids 
Sugars and fatty acids are the main energy sources for the cells. In aerobic organisms, 
these substrates are oxidized to CO2 and H2O with production of ATP through a series of 
reactions known as cellular respiration. The glycolytic pathway which occurs in cytosol, 
converts sugars in pyruvate and produces 2 ATP molecules. In anaerobic conditions, 
pyruvate can be transformed in ethanol or lactate and this pathway is known as alcoholic 
or lactic fermentation. In presence of O2, pyruvate can be completely oxidized with a 
greater ATP production. Therefore it is transported into mitochondria and here it is 
transformed in acetyl-coA thanks to pyruvate dehydrogenase reaction (Perham, 2000; 
Ochoa, 2006).  
In eukaryotic cells, fatty acids are first activated and converted in acyl-coA. Then they are 
imported in mitochondrial matrix thanks to acil-carnitine carrier. In mitochondria fatty 
acids-acyl coA are oxidized through beta oxidation process, a cycle of 4 reactions which 
releases acetyl-coA and acyl-coA. In yeast, however, beta oxidation occurs in 
peroxisomes. Here fatty acids are degraded in acetyl-coA units and are subsequently 
transported in mitochondria through acetyl-carnitine carrier. 
Acetyl-coA units either coming from fatty acids oxidation or glycolysis or from catabolism 
of some aminoacids, are then oxidized in CO2 through Krebs Cycle. 
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1.2.2. Krebs Cycle 
In eukaryotes the Krebs cycle or tricarboxylic acid cycle occurs in mitochondrial matrix 
and plays an important role in utilizing non fermentable carbon sources (Lee et al., 2011). 
This cycle is made of eight reactions (fig.3) and has been proposed in 1947 by H. Krebs. 
When it was first postulated there were still some major areas of uncertainty especially in 
production of citrate (Scheffler, 2008). With the discovery of coenzyme A by Kaplan and 
Lipmann, Ochoa and Lynes were able to show in 1951 that acetyl coA was the 
intermediate in the reaction with oxaloacetate to form citrate (Scheffler, 2008). 
 
Figure 1.3. The reactions of Krebc Cycle (from chemistry.gsu.edu) 
In the cycle two carbons enter as acetyl CoA and leave as CO2. Four oxidation-reduction 
reactions take place to yield reduction potential in the form of three molecules of NADH 
and one molecule of FADH2. A high energy phosphate bond (GTP) is also formed. 
TCA cycle reactions are also an important source of biosynthetic building blocks such as 
α-ketoglutarate and oxalacetate. Indeed these intermediates are used to form aminoacids 
and numerous precursors for other biosynthetic reactions. For example succinyl-coA is a 
precursor for heme synthesis (Scheffler, 2008).  
The Krebs enzymes have been purified and the catalytic mechanisms have been defined. 
All enzymes of TCA cycle are soluble in mitochondrial matrix except one: succinate 
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dehydrogenase. This enzyme is a highly conserved heterotetrameric protein which is 
anchored to the inner membrane and protrude with the catalytic site into the 
mitochondrial matrix (Bardella et al., 2011). This enzyme will be object of discussion in 
the chapter II. 
When Saccharomyces cerevisiae is grown on acetate, a two carbons compound, the Krebs 
cycle itself cannot supply adequate amounts of biosynthetic precursors unless alternative 
reactions are available. Yeast, plants and some microorganisms thus employ a 
modification of the TCA cycle called glyoxylate cycle (fig.4). This cycle produces four 
carbon compounds starting from two acetate units bypassing oxidative decarboxylation 
(Lee et al., 2011).  
 
Figure 1.4. The glyoxylate cycle (http://www.scibio.unifi.it/ourlab/icl.html) 
1.2.3. Oxidative phosphorylation 
A pivotal function of mitochondria is to produce ATP through the process of oxidative 
phosphorylation (OXPHOS) that takes place in the inner membrane. The OXPHOS is a 
fundamental energy-conversion process that transfers electrons from high-energy 
electron donors to oxygen through respiratory enzyme complexes. This process is also 
known as the electron transport chain (ETC). From Krebs cycle intermediates (NADH and 
FADH2), electrons feed into complex I or II and are transferred to complex III, then to 
complex IV and finally to O2. The redox energy released during the electron transfer 
process in complexes I, III, and IV is utilized to actively pump out H+ from the 
mitochondrial matrix to the intermembrane space (Wallace et al., 1988; DiMauro and 
Schon, 2003; Balaban et al., 2005) The redox reactions in the respiratory chain, based on 
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the chemiosmotic theory proposed by Mitchell, produce an electrochemical proton 
gradient that allows H+ to diffuse back to the matrix converting ADP and inorganic 
phosphate (Pi) to ATP through a fifth inner membrane complex (Mitchell and Moyle, 
1967). NADH electrons are sufficient to produce three ATP molecules, while from FADH2 
electrons two ATP molecules are obtained. The electrons are transported through specific 
transporters that are cyclically reduced and oxidized. In the ETC the transporters are: 
- Fe-S centers: are prosthetic groups that contain iron different from heme. 
Inorganic sulfur atoms or cysteine residues coordinate the iron atoms. These 
centers and specifically the iron atoms that pass from Fe2+ to Fe3+ cyclically 
accept electrons one by one.  
- respiratory cytochromes: are mitochondrial proteins bound (covalently or not) to 
heme groups whose iron atom is able to transfer electrons. There are several 
different cytochromes, named with alphabetical letters, which absorb UV light with 
specific adsorption spectra. Typically, c-type cytochromes have a prominent band 
peak at about 550 nm, b-type cytochromes at around 560 nm, and a type 
cytochromes at around 602 nm. 
- Coenzyme Q or ubiquinone: is the only ETC transporter not bound to a protein 
complex. It transports either electrons or protons. There are three redox states of 
coenzyme Q10: fully oxidized (ubiquinone), semiquinone (ubisemiquinone), and 
fully reduced (ubiquinol). 
 
Figure 1.5.Respiratory chain by KEGG pathway 
Respiratory complexes are anchored to the inner membrane and are able to transfer 
electrons across the respiratory chain. These are: 
- Complex I or NADH ubiquinone oxidoreductase is the largest complex of the 
respiratory chain. It has a L shaped structure consisting of a hydrophobic 
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membrane arm and a peripheral arm that protrudes into the mitochondrial matrix 
(Mckenzie and Ryan, 2010). This complex comprises 45 subunits (>900 kDa) in 
mammalian mitochondria, 7 of which (ND1, 2, 3, 4L, 4, 5, 6) are encoded by 
mtDNA. The remaining 38 subunits are encoded by nuclear genes. It contains 6 
iron-sulfur clusters and one flavin mononucleotide cofactor. NADH is oxidized and 
two electrons are transferred to FMN center. These electrons are then transferred 
via iron sulfur clusters to the matrix side to reduce ubiquinone to ubiquinol and 4 
protons are subsequently transferred to the intermembrane space (Saraste, 1999).  
NADH + Q + 5Hi
+ => NAD+ + QH2 + 4 Ho
+ 
Unlike other OXPHOS subunits, however a detailed structure for mammalian 
complex I remains to be determined. The organization of these redox centers 
inside the complex, the roles of accessory subunits unique to mammalian complex 
I and the coupling mechanism between electron transfer and proton pumping are 
still poorly understood. In addition common yeast such as budding and fission 
yeasts which are used as powerful genetics tool for studying the OXPHOS system, 
lacks the complex I but uses a completely different enzyme for electron transfer 
from NADH to ubiquinone, which does not pump protons out the matrix.  
- Complex II or succinate: ubiquinone oxidoreductase or succinate dehydrogenase: 
catalyses the electrons transfer from succinate to coenzyme Q. It is the only 
enzyme which is part both of ETC and Krebs cycle. Indeed it catalyses the 
oxidation of succinate to fumarate and the electrons are channeled to ubiquinone. 
Thus, complex II links the Krebs cycle directly to the ETC (Davis and Hatefi, 1971; 
Hanstein et al., 1971; Davis and Hatefi, 1972). Description of this enzyme will be 
given later in this dissertation. 
- Complex III or ubiquinol- cytochrome c oxidoreductase: catalyses the transfer of 
electrons from ubiquinol to cytochrome c and concomitantly the release of two H+ 
in the intermembrane space. It contains a membrane embedded cytochrome b, 
the Rieske Fe-s protein and cytochrome c1. These are functionally the most 
important subunits since the only ones participating in electron transfer and in 
proton translocation (Scheffler, 2008). Transfer direction is from cytochrome b 
(b562 and b566) through Fe-S centers to cytochrome c. This protein is poorly 
soluble in water and loosely bound to the inner mitochondrial membrane and, 
unlike others cytochromes, is not associate to additional proteins.  
QH2 + Cyt c
3+ + 2 Hi
+ => Q + 2 Cyt c2+ + 4 Ho
+ 
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Complex III like complex I has two reaction centers for ubiquinone, Qn and Qp 
required for the Q cycle. The Qn or quinone reduction center is located in the 
matrix side (N-side) of the inner membrane, it recycles electrons into the quinone 
pool and takes H+ from the matrix. The Qp site is located near to the outer face of 
the inner membrane where protons are released into the intermembrane space. 
The electrons are split in two directions, half are used for recycling and the other 
part is passed through iron-sulfur centers and cyt c1 to cytochrome c. 
- Complex IV or cytochrome c oxidase: consists of 13 proteins and catalyzes the 
electron transfer from cytochrome c to the molecular oxygen, which is the final 
electron acceptor. Cytochrome c is reoxidized and for each electron transferred 
four protons are pumped into intermembrane space. There are two processes 
involved. First four electrons are donated on the IMS side, while four protons are 
taken up on the matrix side, resulting in a transfer of four positive charges across 
the membrane. Second an average of one proton is pumped through the enzyme 
for each electron transferred to oxygen (Brändén et al., 2006). This complex 
contains cytochromes a, a3 and copper atoms to transport electrons. 
4 cyt c2++ 4 H+(s)in + 4H
+
(p)in + O2 => 4 cyt c
3+ + 4H+(p)out + 2 H2O 
- Complex V or ATP synthase: is not a respiratory complex but produces ATP using 
the electrochemical energy released during the oxidative phosphorylation. The H+ 
pumped from the matrix to the inner membrane space are coupled to the electron 
transfers and create the gradient used for ATP synthesis starting from ADP and Pi. 
In addition, the chemical gradient is used for other mitochondrial functions and for 
metabolites transport across the inner membrane. 
 
Figure 1.6. Respiratory mitochondrial complexes: I: NADH-ubiquinone oxidoreductase; II: 
succinate:ubiquinone oxidoreductase; III: ubiquinone -cyitochrome c oxidoreductase; IV: cytochrome c 
oxidase; V: ATP synthase complex; Q: coenzyme Q; cytc: cytochrome c. The blue arrows indicate the 
electrons. 
 
 
 
I
II
III IV V
cytc
Q
4H+ 4H+ 2H+ 3H+
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1.3. The Assembly of the Electron Transfer Chain Complexes 
Despite the compositions, structures and functions of the electron transport complexes 
are well understood, the biogenesis mechanisms are not completely elucidated. 
Furthermore, the mechanisms and the pathways leading to the assembly of these 
multisubunit complexes with integral and peripheral membrane subdomains, to the 
incorporation of prosthetic groups such as Fe-S centers or heme and other metal centers, 
are still an intriguing challenge to be understood. In order to gain insights into these 
mechanisms, several approaches have been developed. One of these approaches takes 
advantage of the model organism S.cerevisiae  whose specific knockouts are available and 
can be made easily. The knockout strains can be used to characterize intermediates that 
accumulate in the absence of a particular subunit for a complex of interest. In other 
organisms, the possibility to find suitable mutants can help to identify assembly 
intermediates. Despite several ETC subunits mutations have been identified, the difficulty 
is given by the fact that when specific subunits are absent due to mutations, some or all 
the remaining subunits fail to assemble and are rapidly degraded (Scheffler, 2008). A 
significant impact on the study of the ETC complexes has been given by Schagger and 
colleagues who developed the Blue-Native gel electrophoresis. This method allows to 
achieve in one gel the fractionation of all complexes in their native form (Schägger 1995; 
Schägger 2001; Schägger 2002; Schägger et al., 2004). However, this technique requires 
the solubilization of mitochondria in detergents and therefore there is the possible risk to 
destroy in vivo the existing unstable intermediates. A brief description of the state of art 
about the ETC assembly will be now discussed. As regards the assembly of complex I, the 
human model will be the object of discussion and the motivations are described below. 
For the other complexes, the studies in yeast will be discussed. 
 
- Assembly of mitochondrial complex I 
Complex I is the largest component of the respiratory chain. It consists of 45 different 
subunits which must be assembled correctly to form the properly functioning mature 
complex of ~1 MDa (Lazarou et al., 2009). Complex I dysfunction is the most common 
oxidative phosphorylation (OXPHOS) disorder in humans and defects in the complex I 
assembly process are often observed. This assembly process has been difficult to 
characterize because of its large size, the lack of a high specific resolution structure and 
its dual control by nuclear and mitochondrial DNA. However, in recent years, some of the 
atomic structure of the complex I have been resolved and new insights into complex I 
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assembly have been generated. Furthermore, a number of proteins have been identified 
as assembly factors for complex I biogenesis and many patients carrying mutations in 
genes associated with complex I deficiency and mitochondrial diseases have been 
discovered (Mimaki et al., 2011). In addition, the yeast S. cerevisiae lacks a true complex 
I (there is a single subunit NADH-Ubiquinone Oxidoreductase, Ndi1p, that catalyzes a 
similar reaction, see Yang et al., 2011 for details) and this has prevented such detailed 
analyses into assembly seen for other complexes of the respiratory chain (Lazarou et al., 
2009).  
The study of cI assembly has employed various eukaryotic model systems such as the 
green alga Chlamydomonas reinhardtii, the fungus Neurospora crassa, the nematode 
Caenorhabditis elegans and cultured mammalian cell lines which have been recently 
reviewed and described by Mimaki et al., 2011. The positions of each subunit within this 
structure have not yet been fully defined; however, treatments with mild chaotropic 
agents can dissociate the complex into four subcomplexes (Iα, Iβ, Iλ, Iγ) allowing the 
identification of subunits within each subcomplex (Sazanov et al., 2000; Carroll et al., 
2003; Finel et al., 1992). As regards the nomenclature of these subunits the nuclear 
encoded subunits contain the prefix “NDU” (NADH-dehydrogenase-ubiquinone) and the 
mtDNA encoded subunits the prefix “ND” (NADH-dehydrogenase). The assembly factors, 
furthermore, contain the prefix “NDUFAF”: NDU for NADH dehydrogenase, F for alpha 
subcomplex, AF as assembly factor plus a number indicating when it was first named 
(Mckenzie and Ryan, 2010). 
 
Figure 1.7.Complex I intermediates 1–6 correspond to intermediates described by Vogel and colleagues 
(Vogel et al., 2007) 
Through analyses using tagged intermediates, it was shown that during the early stages 
of human complex I assembly, intermediate 1 is formed by the addition of subunits 
NDUFS3 and NDUFS2. The subsequent integration of subunits NDUFS7 and NDUFS8 
forms intermediate 2 (fig.7). These four subunits are part of the 14 “core” mammalian 
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subunits (each with a homolog in complex I from E.coli) and form part of the peripheral 
matrix arm which contains the evolutionarily conserved hydrogenase module (Q module) 
(Mckenzie and Ryan, 2010). With the addition of NDUFA9 (and possibly other subunits), 
intermediate 3 is assembled and subsequently anchored to the membrane by the 
assembly factors Ndufaf3 (C3orf60) and Ndufaf4 (C6orf66). Here, intermediate 3 is 
assembled with the ND-containing membrane arm intermediate „„a‟‟ to form the 400 kDa 
intermediate 4. A second membrane arm intermediate of 460 kDa, intermediate „„b‟‟, is 
also formed and is assembled from the membrane arm subunits ND2, ND3, ND6, and 
NDUFB6 and is associated with the assembly factors Ndufaf1 (CIA30) and Ecsit. 
Intermediate 4 and „„b‟‟ assemble together to form intermediate 5 at which stage 
NDUFA13 is incorporated (Vogel et al., 2007). The subunits ND4 and ND5 are then 
assembled into the growing complex with other subunits in a small membrane arm 
intermediate (intermediate c). The resulting ~830 kDa complex is the intermediate 6. The 
assembly factors Ndufaf1, Ndufaf2, Ecsit, Ndufaf3, and Ndufaf4 remain associated with 
this intermediate until the last stage of assembly, where intermediate „„d‟‟ (which contains 
the N module) is assembled to form mature complex I. 
Another specific complex I assembly factors is Ind1p (iron-sulfur protein required for 
NADH dehydrogenase): it is a mitochondrial protein which binds iron-sulfur clusters via a 
conserved CXXC motif (Bych et al., 2008). It is important for the assembly of the eight Fe-
S clusters present in the complex I. Deletion of Ind1p in the yeast Yarrowia lipolitica 
(S.cerevisiae lacks this gene) results in a specific defect in the enzymatic activity of 
complex I but not in other mitochondrial Fe-S containing enzymes such as aconitase, 
succinate dehydrogenase or cytochrome bc1 complex (Bych et al., 2008). 
 
The assembly of complex II will be discussed in the chapter II. 
 
- Assembly of complex III 
The bc1 complex or complex III is a homodimeric complex localized in the inner 
mitochondrial membrane and each monomer is composed of ten (eleven in mammals) 
different non redundant subunits (Zara et al., 2009). Three of them are the catalytic 
subunits: cytochrome b, cytochrome c1 and the Rieske protein (ISP), found in all 
organisms. The remaining subunits (core protein 1, core protein 2, Qcr6p, Qcr7p, Qcr8p, 
Qcr9p and Qcr10p) do not contain any prosthetic group and their functions are still poorly 
understood. The yeast crystal structure does not contain Qcr10p even if this protein is an 
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authentic subunit of the complex likely analogous to mammalian SU11 which has been 
seen in the bovine structure (Smith et al., 2011). Mammalian complexes contain an 
additional subunit not present in S.cerevisiae, SU9, which is embedded between Cor1 and 
Cor2 and corresponds to the presequence of the Rieske Fe/S protein (Smith et al., 2011).  
Only cytochrome b subunit is encoded by mtDNA; the other subunits are nuclear encoded 
and are imported post translationally into yeast mitochondria (Zara et al., 2009).  
 
Figure 1.8. Comparison of eukaryotic bc1 complex subunit nomenclature (Smith et al., 2011). 
The assembly status of the cytochrome bc1 complex has been analyzed in distinct yeast 
deletion strains in which genes for one or more subunits were deleted. In all the yeast 
strains tested, a bc1 sub-complex of approximately 500 kDa was found when the 
mitochondrial membranes were analyzed by BN-PAGE. The subsequent molecular 
characterization of this sub-complex, carried out in the 2D-BNGE and immunodecoration, 
revealed the presence of two catalytic subunits, cytochrome b and cytochrome c1, 
associated with the non catalytic subunits core protein 1, core protein 2, Qcr7p and Qcr8p 
as described below (Zara et al., 2009). 
Zara and colleagues have systematically investigated the effects of single or double 
deletions of these supernumerary proteins or Cyt b on the formation of an active complex 
III. Some of these subunits (QCR6p, QCR10p) were dispensable as single deletions 
whereas most double deletions had a significant impact on the assembly of a functional 
complex (Scheffler, 2008). Through these mutants and several studies, an assembly 
scheme was developed (fig.9) and indicated that the central hydrophobic core of the bc1 
complex was represented by the cytochrome b⁄Qcr7p⁄Qcr8p sub-complex (Crivellone et 
al., 1988; Grivell, 1989; Zara et al., 2004). Indeed deletions in one of these three genes 
lead to the absence of the other two proteins, suggesting that cytochrome b, Qcr7p and 
Qcr8p could functionally interact (Crivellone et al., 1988; Zara et al., 2004;). This 
subcomplex is referred to as the „membrane core sub-complex‟. Furthermore the authors 
indicated the presence of a larger core structure of the bc1 complex that included 
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cytochrome b⁄Qcr7p⁄Qcr8p⁄cytochrome c1⁄core protein 1⁄core protein 2. A significant 
difference between the smaller and the larger sub-complexes was the fact that the first 
one (cytochrome b⁄Qcr7p⁄Qcr8p) was very unstable and, consequently, its identification 
was extremely difficult, whereas the second (cytochrome b⁄Qcr7p⁄Qcr8p /cytochrome 
c1⁄core protein 1⁄core protein 2) was characterized by a much higher stability (Zara et 
al., 2009). Therefore they speculated that the larger bc1 core structure could acquire a 
higher stability against proteolytic degradation after incorporation of the two core 
proteins.  
 
Figure 1.9. Schematic model depicting the putative pathway of assembly of complex of the yeast cytochrome 
bc1 complex (Zara et al., 2009) 
So the large bc1 core structure was capable of binding the chaperone protein Bcs1p. 
What is known is that Bcs1p is primarily required for the incorporation of Rip1p (ISP), 
even if further functions cannot be excluded. A possible role of this chaperone in the 
stabilization of the core structure of the bc1 complex can be excluded on the basis of the 
existence of the 500 kDa bc1 sub-complex also in the Δbcs1 strain. In addition, the fact 
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that the molecular mass of the bc1 sub-complex found in this deletion strain is more or 
less similar to that of the sub-complex found in all the other deletion strains would 
suggest that the Bcs1p is present as a monomer in the bc1 core structure. The role of this 
chaperone protein has also been investigated in humans, in which molecular defects of 
BCS1 are associated with mitochondrial encephalopathy (Fernandez-Vizarra et al., 2007). 
The so formed bc1 core structure associated with Bcs1p, binds Qcr6p and or Qcr9p and 
these proteins are not required for the binding of Bcs1p. However both Qcr9p and Bcs1p 
are required for the subsequent insertion of ISP into the bc1 sub-complex, but the 
presence of only one of these two subunits does not substitute for the other. After the 
addition of the essential ISP, the binding of the last subunit (Qcr10p) finally occurs. These 
findings are in agreement with the previous studies suggesting that ISP and Qcr10p 
represent the last subunits incorporated into the bc1 complex before dimerization (Zara et 
al., 2009). The dimerization process is still unknown because it is not clear when this 
process takes place. The 500 kDa complex could represent either a monomeric bc1 
complex in association with various unidentified assembly factors or a dimeric bc1 
complex perhaps associated with monomeric Bcs1p (Smith et al., 2011). Recently new 
complex III assembly factors have been found either in mammals and yeast. TTC19, 
which encodes tetratricopeptide repeat (TPR) domain, has been identified in individuals 
coming from two families affected by progressive encephalopathy associated with a 
profound cIII deficiency and accumulation of cIII-specific assembly intermediates (Ghezzi 
et al., 2011). Curious thing is that orthologs to TTC19 in other eukaryotes (plants or 
fungi) are not known. On the contrary, the assembly factor Bca1p has been identified only 
in fungi and controls an early step in complex III assembly. The authors suggested that 
the supra-molecular organization of Bca1p is dependent upon the assembly level of 
complex III (Mathieu et al., 2011).  
 
- Assembly of complex IV 
 
Mitochondrial cytochrome c oxidase (COX) is a multimeric copper- heme A enzyme of the 
mitochondrial respiratory chain. It is formed by subunits of dual genetic origin whose 
assembly, intricate and highly regulated, have been recently reviewed by Barrientos and 
colleagues. Eukaryotic COX is formed by 11-13 subunits (11 in the yeast S. cerevisiae and 
13 in mammals) and the catalytic core is formed by three mitochondrial DNA encoded 
subunits, Cox1, Cox2, Cox3 conserved from prokaryotes to mammals (Soto et al., 2011). 
A significant impact on the study of the assembly of this complex was given by the yeast 
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S.cerevisiae and by its knockout mutants. However at least one interesting gene 
(SURF1/Shy1) was identified from a molecular genetic analysis of human patients with 
Leigh Syndrom, a mitochondrial disease discussed further in this dissertation (Scheffler, 
2008).  
The process of COX assembly has been subject of intense investigations over the last 50 
years using different approaches and it is still actively investigated nowadays (Soto et al., 
2011). This process seems to be a linear process with the sequential addition of different 
subunits and cofactors in ordered manner. The concept of a sequential addition was 
developed in the early 1980s thanks to the data obtained from studies that used rat liver 
mitochondria and followed the incorporation of radiolabeled subunits into the COX 
complex (Wielburski and Nelson, 1983). The model was later confirmed by analyses of the 
human enzyme performed by BN-PAGE (Soto et al., 2011). By analyzing the formation of 
assembly intermediates, it was concluded that assembly initiates around a seed formed by 
subunit 1 and proceeds with the formation of several discrete assembly intermediates 
probably representing rate-limiting steps in the process (Soto et al., 2011). A recently 
simplified model for the process of COX assembly is represented in fig. 10. After the 
synthesis of mtDNA subunits forming the core and their insertion in the inner membrane, 
Cox1p and Cox2p are maturated by the addition of metal cofactors. At some point, 
substrate-specific chaperones bind Cox1p and Cox2p to maintain them in an assembly-
competent state. A specific Cox3p chaperone has not yet been identified. Only after the 
Cox1p maturation, the nuclear DNA-encoded Cox5p and Cox6p subunits can be added as 
well as the other core subunits and the rest of the accessory subunits to form the 
holoenzyme (Soto et al., 2011). 
 
 
Figure 1.10. Simplified model for the process of COX assembly (Soto et al. 2011). 
In yeast, COX assembly requires the assistance of at least 30 nuclear gene products 
acting at all stages of the assembly process (Fontanesi et al., 2006; Fontanesi et al., 
2008) and recent studies suggested that the assembly requires the accumulation of COX 
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constitutive subunits in a defined stoichiometric ratio (Fontanesi et al., 2011). A list of all 
genes involved in this biosynthetic process is reported below. 
 
 
 
Figure 1.11. Homologue COX subunits and COX assembly factors in the yeast Saccharomyces cerevisiae  and 
human (Soto et al.,  2011). 
19 
 
1.4. Supercomplex organization state of the OXPHOS system 
 
The OXPHOS complexes I-IV and complex V are multisubunit enzymes which are 
embedded in the lipid bilayer of the inner mitochondrial membrane. The use of Blue 
Native gel electrophoresis allowed to understand better how these complexes are 
organized in the membrane. Indeed the OXPHOS complexes besides their expected 
position as “monomer” in the gel migrate also as bands of higher molecular weight. This 
indicated that the mitochondrial complexes of the OXPHOS system physically interact with 
each other to form supramolecular structures in the inner mitochondrial known as 
supercomplexes or respirasomes (Wittig et al., 2006; Bultema et al., 2009; Strecker et al., 
2010). It is thought that since the electron transport chain is one of the major 
contributors to free radicals in the cell, respirasomes could minimize the generation of 
reactive oxygen species (ROS) by allowing a more efficient electron transfer and substrate 
channeling among the complexes avoiding thus the diffusion of reactive intermediates 
(Genova et al., 2008; Lenaz and Genova, 2010). The assembly of supercomplexes has 
been observed in a wide variety of organisms, including bacteria, plants, fungi, and 
mammals, although their composition might vary from organism to organism (Diaz et al., 
2012). Mammalian supercomplexes are composed mainly by CI, CIII, and CIV in different 
stoichiometries (I/III, I/III2, I2III2, I/III/IV, I/III2/IV, I/III/IV2, III/IV, and III2/IV1-2) 
(Schägger and Pfeiffer, 2001; Wittig et al., 2006). In yeast S.cerevisiae where complex I 
is absent, complex III and complex IV have been found in organized supramolecular 
structures (Stuart, 2008). In particular bc1 is capable of forming three complexes: its 
dimeric form and supercomplexes with either one or two monomers of complex IV 
(III2,III2-IV, III2-IV2) (Smith et al., 2011). It is thought that the aggregation state of these 
complexes is influenced by the lipid composition rather than phospholipids amount of the 
inner mitochondrial membrane. Indeed it was shown that cardiolipin (CL) is specifically 
required for super-complex association (Lenaz et al., 2010). Studies in a CL-lacking yeast 
mutant demonstrated that the III2-IV2 super-complex was significantly less stable than 
supercomplexes in the parental strain (Pfeiffer et al., 2003; Zhang et al., 2003). It is 
suggested that the putative protein–protein interaction of COX and Complex III involves 
CL and phosphatidyl ethanolamine which is tightly embedded in the cIII (Lange et al., 
2001). In addition, a subpopulation of the cIII-COX complex has been found to interact 
with TIM23 machinery and also to associate with the Shy1 and Cox14 proteins (van der 
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Laan et al., 2006; Mick et al., 2007; Saddar et al., 2008; Stuart, 2009). In yeast another 
supercomplex described is the dimeric ATP synthase complex. 
 
1.5. OXPHOS Defects 
 
In the late 1980s, human pedigrees with mtDNA mutations and a phenotype were 
discovered and the term “mitochondrial disease” was introduced (Scheffler 2008). Today 
the term “mitochondrial diseases” indicates a vast group of clinical phenotypes 
characterized by biochemical and genetic abnormalities of oxidative phosphorylation 
(OXPHOS) (Zeviani and Carelli, 2007). Actually all the diseases with impaired 
mitochondrial activities are considered mitochondrial diseases.  
There are a number of genetically determined abnormalities of mitochondria that cause 
human diseases. The mitochondrial genome accumulates mutations at a significantly 
faster rate compared to the nuclear genome and several factors contribute to this higher 
mutational rate: the absence of protective histones, the lack of effective repair 
mechanisms, the high mtDNA replication rate increasing the likelihood of errors and the 
close proximity of mtDNA molecules to the respiratory chain complexes where they are 
exposed to high levels of reactive oxygen species (ROS) (Howell et al., 1996; Jazin et al., 
1998; Raha and Robinson, 2000; Yu-Wai-Man et al., 2011). 
Since there are a large numbers of copies of mtDNA within the cells (from 1000 to 
100000 depending on the cell type), these can be identical in a healthy individual at birth, 
a condition known as homoplasmy (Chinnery, 2003). By contrast, two populations of 
mtDNA molecules may also be present, one being normal (wild type) and the other being 
mutated (Scheffler, 2008) and in this case the definition is heteroplasmy (Holt et al., 
1988). Single cell studies have shown that the proportion of mutant mtDNA must exceed 
a critical threshold level before the cell expresses a biochemical defect of the 
mitochondrial respiratory chain (Schon et al., 1997). This threshold level varies from 
tissue to tissue and partly explains the tissue-selectivity seen in mitochondrial disorders 
(Wallace, 1994). The percentage level of mutant mtDNA can also vary between and 
within individuals harbouring a pathogenic mtDNA defect and this partly explains the 
clinical variability that is a hallmark of mtDNA disorders (Macmillan et al., 1993). 
Mitochondrial disorders usually involve organs that are heavily dependent upon the 
energy produced by mitochondria such as brain, peripheral nerves, limb, muscles, heart 
and hormone-producing glands. These disorders can cause muscle weakness on its own 
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and are usually associated with neurological, heart and hormone problems including 
diabetes (Chinnery et al., 2009). They are usually progressive and often cause significant 
disability and premature death (Leonard and Schapira, 2000; DiMauro and Schon, 2001). 
Based upon recent epidemiological studies, mitochondrial disorders affect at least 1 in 
5000 of the general population (Smeitink et al., 2006).  
Mitochondrial diseases are classified in two distinct groups depending on they are caused 
by mtDNA mutations or nuclear DNA mutations of genes involved in respiratory chain. As 
regards the first group, mtDNA mutations are inherited down the maternal line, thus the 
specific mtDNA disorders either are passed from mother to child or they affect sporadic 
cases (Chinnery et al., 1998). These disorders may be caused by: 
- mtDNA point mutations: are maternally inherited. They include aminoacids 
substitutions and protein synthesis mutations (tRNA, rRNA, mRNA that are then 
translated in proteins). Individuals with point mutations in their mtDNA are 
generally heteroplasmic and the mutant DNA is inherited in a variable proportion 
from the maternal germline. Even if more than one hundred point mutations have 
been described in association with an extremely heterogeneous spectrum of 
clinical presentations, only a few of them are frequent and associated with well-
defined clinical syndromes. The A3243G mutation in the tRNALeu gene (UUR) is for 
example responsible for the mitochondrial encephalomyopathy with lactic acidosis 
and stroke-like episodes (MELAS) syndrome (Goto et al., 1990). It is characterized 
by stroke like episodes due to focal brain lesions, lactic acidosis and red ragged 
fibers. Other associated manifestations are headache, vomiting, ataxia, diabetes or 
cardiomyopathy. Other point mutations associated with MELAS have been 
reported, although they are much rarer than the A3243G (www.mitopedia.org).  
As regards mitochondrial genes encoding structural proteins, mutations have been 
reported in Leber‟s hereditary optic neuropathy (LHON) and in Neurogenic, Ataxia 
and Retinitis Pigmentosa (NARP)/Leigh syndrome (Ruiz-Pesini et al., 2007). LHON 
is characterized by adult onset blindness due to retinal ganglia cell death followed 
by optic nerve atrophy (Wallace et al., 1988). The majority of patients with LHON 
(90-95%) harbors one of three mtDNA point mutations affecting in subunits of 
complex I: m.3460G>A in ND1 subunit (Howell et al., 1991; Huoponen et al., 
1991), m.11778G>A in ND4 (Wallace et al., 1988) and m.14484T>C in ND6 
(Johns et al., 1992; Mackey and Howell, 1992). The m.11778G>A mutation was 
identified in 1988 by Wallace et al., and it was the first identified mtDNA 
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substitution confirmed to cause human disease. Other mutations, all present in 
complex I mtDNA genes, have recently been identified.  
NARP or Neurogenic muscle weakness, ataxia, retinitis pigmentosa is a disease 
caused by T8993G mutation in the gene encoding subunit 6 of mitochondrial 
ATPase (complex V of the respiratory chain) (Holt et al., 1990). In these patients 
there is a significant defect in the rate of ATP synthesis. The same mutation when 
present in >90% of total mitochondrial genomes, leads to the a more severe 
disease called maternally inherited Leigh syndrome (MILS). 
- mtDNA rearrangements: these mutations can be mtDNA deletions or duplications 
and are associated with severe progressive mitochondrial diseases which are often 
lethal. They are usually sporadic, heteroplasmic and unique and frequently occur 
between directly repeated sequences, suggesting that they are caused by de novo 
rearrangements arising during oogenesis or early development (Rötig, 2010). 
mtDNA deletion are usually associated with Kearns-Sayre syndrome, Progressive 
external ophthalmoplegia and Pearson‟s syndrome.  
- mtDNA copy number mutations (depletions): these are quantitative reductions of 
mtDNA amount without mutations or rearrangements of mtDNA. These disorders 
are usually infantile with a progressive course and are caused by mutations in the 
nuclear genes such as Thymidine kinase 2 (TK2) in the myopathic form, 
Deoxyguanosine kinase (DGUOK) or POLG in the hepatic form (Mandel et al., 
2001; Saada et al., 2001; Naviaux and Nguyen, 2004). The most involved organs 
are skeletal muscle and heart, liver and brain (www.mitopedia.org).  
 
The second group is represented by mutations in the nuclear genome. Mitochondria have 
limited autonomy since they heavily rely on the nuclear genome for their biogenesis. 
Mitochondrial disorders can therefore arise secondary to both primary mtDNA mutations 
and nuclear genetic defects which disrupt mitochondrial-related proteins (Yu-Wai-Man et 
al., 2011). 
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Figure 1.12. Mitochondrial and nuclear-encoded subunits of the mitochondrial respiratory chain complexes 
(Yu-Wai-Man et al. 2011). 
 
Because of the extreme complexity of OXPHOS and its peculiar genetic organization, the 
number of genes potentially involved in disease is enormous and tends to coincide with 
the size of the mitochondrial proteome itself (Calvo et al., 2006). Over 90% of 
mitochondrial proteins are expressions of nuclear genes and these proteins can be 
grouped in three categories: 
1. structural components of the respiratory chain 
2. proteins that control OXPHOS or mtDNA metabolism 
3. proteins indirectly correlated to OXPHOS 
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Figure 1.13. Nuclear mitochondrial disorders (Yu-Wai-Man et al. 2011) 
The most common and well known group of diseases associated with abnormalities in the 
nuclear genes related to OXPHOS system is the Leigh Syndrome. In about 30% of the 
cases the biochemical defect is a profound decrease in the activity of Complex IV activity 
(cytochrome c oxidase, COX) and the genetic alteration is due, in most cases, to 
mutations in an assembly gene of complex IV, called SURF-1 (Dahl 1998; Tiranti et al., 
1998; Zhu et al., 1998; Tiranti et al., 1999; Borisov 2002). In other cases, the biochemical 
defect is found in Complex I or Complex II of the respiratory chain. In particular, 
mutations in the subunits NDUFS1, NDUFS4, NDUFS7, NDUFS8, NDUFV1 of Complex I 
and mutations in SDHA of complex II have been identified in some patients. 
A few mutations of complex III are known. These mutations have been associated with 
two genes encoding CIII subunits, UQCRB and UQCRQ (Haut et al., 2003; Barel et al., 
2008) and with BCS1L gene which is involved in complex III assembly (Tuppen et al., 
2010). 
Nuclear gene mutations are also associated with multiple mtDNA deletions. Indeed in 
2001, the first nuclear genes, POLG1 and PEO1, were identified among families with 
autosomal - dominant chronic progressive external ophthalmoplegia (CPEO) associated 
with multiple mtDNA deletions (Spelbrink et al., 2001; Van Goethem et al., 2001). Also 
the nucleotide transporter ANT1 has been associated with this disease (Van Goethem et 
al., 2002). Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an 
25 
 
autosomal recessive disease associated with both deletions and mtDNA depletion due to a 
mutation in thymidine phosphorylase causing an imbalance in mitochondrial nucleotide 
pool (Bardosi et al., 1987). 
 
Figure 1.14. Gene mutations resulting in specific respiratory chain complexes (Rötig, 2010) 
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Figure 1.15. The mitochondrial respiratory chain (RC). The diseases caused by mutations in mtDNA (above 
the RC) and in nDNA (below the RC) are listed according to the correspondingly affected RC complex 
(DiMauro and Schon, 2008). 
 
1.6. Diseases associated with impaired SDH activity 
 
The various nuclear genes encoding RC subunits have all been identified and mapped. 
The RC complexes contain from four (CII) to 45 subunits (CI) each. Therefore, a 
functional complex requires structural integrity and tight regulation of each of its subunits 
(Rötig, 2010). Mutations in one of these genes lead to neurodegenerative diseases. 
However, mutations in one of subunits of complex II are associated with different 
diseases not necessarily responsible for neurodegenerative disorders. Indeed, germinal 
mutations in SDHA mutations cause Leigh Syndrome while mutations in the three other 
genes encoding subunits B, C and D of CII have been reported in hereditary 
paraganglioma and pheochromocytoma (HPGL/PCC), suggesting that such „housekeeping‟ 
genes may be involved in carcinogenesis (Baysal, 2008). It has been hypothesized that 
SDH mutations cause an accumulation of succinate and reactive oxygen species (ROS), 
which could act as downstream signaling molecules to activate hypoxia-inducing pathways 
(Baysal, 2008). Interestingly, also mutations in genes encoding for the assembly factors, 
SDHAF1 and SDHAF2, cause both typical mitochondrial diseases and cancer (Ghezzi et al., 
2009; Hao et al., 2009). 
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Figure 1.16. Succinate dehydrogenase complex (SDH) in the electron transport chain and Krebs cycle 
(Bardella et al. 2011) 
 
SDHA The first mutation in a nuclear gene encoding a RC subunit was reported in 1995 
in two sisters with Leigh syndrome and CII deficiency (Rötig, 2010). The pathogenic 
mutation was in the SDHA gene encoding the flavoprotein of CII (Bourgeron et al., 1995). 
Mutations in the same gene were subsequently reported in other patients affected by 
Leigh Syndrome (Parfait et al., 2000; Van Coster et al., 2003; Horvath et al., 2006). Leigh 
Syndrome is a genetically heterogeneous disease with multiple causes for alteration in 
mitochondrial function including defect or deficiencies in: electron transport chain 
Complex I-V, the pyruvate dehydrogenase complex (PDHC), mitochondrial DNA (mtDNA) 
and mutations in the SURF1 gene (Rutter et al., 2010). A single case of a pathogenic 
SDHA mutation (c.1664 G>A, p.Gly555Glu) not associated to Leigh Syndrome has been 
described in a patient with a lethal infantile presentation, which has led to death due to 
respiratory infection and acute hypoglycemia, before any sign of the syndrome could 
develop (Van Coster et al., 2003). The same SDHA missense mutation, which was 
reported to cause a multisystemic failure leading to neonatal death (Van Coster et al. 
2003) and a relatively mild Leigh syndrome (Pagnamenta et al., 2006), was also described 
in a familial neonatal isolated cardiomyopathy (Levitas et al., 2010). Recently germline 
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mutations in SDHA have been identified in patients affected by apparently sporadic 
(para)sympathetic paragangliomas and pheochromocytomas (Korpershoek et al. 2011).  
Even if SDHA is part of the same complex which comprise SDHB, SDHC, SDHD there are 
no evidences that mutations in these other SDH genes could lead to neurological 
disorders. The molecular mechanism causing these diseases is not well understood. 
Bourgeron et al., reported an increased sensitivity of SDHA to the inhibitory effect of 
oxalacetate and speculated that the mutation could alter SdhAp conformation or redox 
state which might alter enzyme catalysis and response to oxalacetate (Bourgeron et al., 
1995; Rutter et al., 2010). 
SDHB (PGL4) The PGL4 syndrome, which was identified for the first time by Astuti in 
2001, is due to mutations in the SDHB gene which encodes an iron-sulfur protein that 
together with SDHA constitutes the catalytic domain of SDH complex. SDHB mutations 
mainly predispose to extra-adrenal paraganglioma (PGLs) with high malignant potential 
and to a lesser extent to adrenal pheochromocytomas (PCCs) and head and neck PGLs 
(Young et al., 2002; Neumann et al., 2004; Benn et al., 2006; Brouwers et al., 2006; 
Timmers et al., 2007). SDHB mutations are some of the most common germline 
mutations in Familial Paraganglioma Syndrome (FPS) and 98 different alterations have 
been identified in 216 index cases (Ricketts et al., 2010). The majority of these SDHB 
mutations were missense mutations (46%), followed by frameshift mutations (23%) and 
splicing mutations (13%). The mean age of PGL diagnosis has been reported from 27.4 
(PCCs) to 42.3 (HNPGLs) years old by one study (Ricketts et al., 2010) and ~ 30 years old 
by another study (Timmers et al., 2007) but there are cases in which the index cases 
have been diagnosed before 10 years of age (Benn et al., 2006; Mora et al., 2006; 
Armstrong et al., 2009; Ricketts et al., 2010). This suggests that tumor screening of 
asymptomatic SDHB carriers should start as early as 10 years of age (Bardella et al., 
2011). 
SDHC (PGL3) The PGL3 syndrome is caused by mutations in the SDHC gene. SDHC 
constitutes the membrane domain of complex II together with SDHD. The association of 
SDHC (1q21) mutations with PGL3 wad described for the first time by Niemann and Muller 
in 2000 (Niemann and Müller 2000). SDHC mutations were originally believed to be 
associated only with HNPGLs but recently rare cases of adrenal PCCs and extraadrenal 
PGLs were reported (Burnichon et al., 2009; Mannelli et al., 2007; Mannelli 2009; 
Peczkowska et al., 2008; Pasini et al., 2008). Germline SDHC mutations appear to be less 
frequent than SDHB and SDHD mutations and a limited number of SDHC mutation carriers 
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have been identified worldwide (Niemann and Müller, 2000; Bauters et al., 2003; 
Niemann et al., 2003; Baysal et al., 2004; Schiavi et al., 2005; Bayley et al., 2006; 
Mannelli et al., 2007; Peczkowska et al., 2008; Boedeker et al., 2009; Burnichon et al., 
2009; Cascón et al., 2009; Neumann et al., 2009). In general, the clinical features of 
SDHC-associated cases are similar to those found in patients with sporadic HNPGLs. 
Mutation carriers typically present with solitary head and neck tumors with incomplete 
penetrance and a very low tendency to malignant transformation (Schiavi et al., 2005). 
Only a single case of malignant catecholamine-producing carotid body tumor has been 
reported in a patient with IVS5 +1 G>T SDHC mutation (Niemann et al., 2003). 
SDHD (PGL1) The hereditary syndrome PGL1 was identified in 2001 by Baysal et al., 
and is caused by mutations in the SDHD gene (11q23) which encodes the other 
membrane – anchoring subunit of complex II. SDHD mutations are typically associated 
with multifocal HNPGLs and less frequently with adrenal PCCs and extra-adrenal PGLs, 
which are usually benign (Neumann et al., 2004; Benn et al., 2006; Burnichon et al., 
2009). Rare cases of metastatic HNPGLs have been described within SDHD mutation 
carriers and their estimated prevalence is 0-10% (Astrom et al., 2003; Neumann et al., 
2004; Amar et al., 2005; Benn et al., 2006; Ogawa et al., 2006; Havekes et al., 2007; 
Papaspyrou et al., 2008; Burnichon et al., 2009; Ricketts et al., 2010). 
Although PCCs and extra-adrenal PGLs are relatively rare in patients with SDHD germline 
mutations, recently Ricketts described that SDHD mutations predicted to result in an 
absent or unstable SdhD protein were associated with an increased risk of PCCs and 
extra-adrenal PGLs, compared to missense mutations or in-frame deletions, which were 
not predicted to impair protein stability (Ricketts et al., 2010). The mean age of PGL 
diagnosis in PGL1 patients ranges from 20.7 (PCCs) to 40.1 (HNPGLs) years old 
(Neumann et al., 2004; Ricketts et al., 2010). SDHD-related diseases have been 
characterized by a parent-of-origin effect since it is transmitted only when the mutated 
allele is inherited from the father (Baysal et al., 2002; Neumann et al., 2004; Benn et al., 
2006). This pattern of inheritance suggested maternal genomic imprinting (suppression) 
of this gene. The influence of genomic imprinting in disease susceptibility is well 
recognized in developmental disorders, such as Prader-Willi/Angelman syndrome (Nicholls 
and Knepper, 2001) but the mechanisms underlying the imprinted penetrance of SDHD 
mutations (and SDHAF2 mutations, both genes present on the long arm of chromosome 
11), are poorly understood, because this PGL gene does not reside in known imprinted 
domains and molecular evidence of imprinting has been lacking (Baysal et al., 2011). 
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However, recently, Baysal and Shadel indicated a mechanism explaining this maternal 
inheritance and the parent-of-origin-dependent tumor susceptibility through a maternal 
downregulation of SDHD. Indeed, they identified imprinted methylation within an 
alternative promoter for a large intergenic non coding RNA located at the boundary 
between the SDHD locus and a flanking gene desert. Partial inactivation of SDHD by 
imprinting might provide an advantage for early detection of hypoxia, because PGL 
tumors, where SDH is completely inactive, show constitutive activation of hypoxia-
inducible pathways (Gottlieb and Tomlinson, 2005; Baysal, 2008; Raimundo et al., 2011). 
SDHAF2 (SDH5; PGL2) The SDHAF2 gene has been identified recently by Hao et al., 
and is known as SDH5. It is a susceptibility gene for the PGL2 syndrome and was first 
described in a previously identified large Dutch kindred with multiple HNPGLs (Baars et 
al., 1992; Mariman et al., 1995). The position of the involved gene in these affected 
families was localized by linkage analysis to 11q11.3, but for almost two decades the 
specific gene remained unknown. This gene encodes a highly conserved protein, 
necessary for the incorporation of FAD cofactor in the subunit A of the SDH complex. 
Correct flavination of the SDHA subunit is essential for the SDH enzyme activity (Hao et 
al., 2009). To date SDHAF2 mutations have been associated to benign, often multifocal 
head and neck paragangliomas, with young age of onset (Hao et al., 2009; Bayley et al., 
2010; Kunst et al., 2011). 
SDHAF1 (SDH6) The identification and the diseases associated to this gene, will be 
discussed in chapter 2 of this dissertation.  
 
Figure 1.17. Summary of clinical features of the four described familial paraganglioma syndromes (Rutter et 
al. 2010) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter II: 
SDH6 a new nuclear gene required for SDH assembly 
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2.1. The complex II or succinate dehydrogenase (SDH) 
 
2.1.1. The SDH structure 
Succinate dehydrogenase (SDH) is a ubiquitous mitochondrial enzyme that catalyzes the 
oxidation of succinate to fumarate and the generated reducing equivalents are transferred 
to ubiquinone (coenzyme Q) in the electron transport chain (ETC): 
Succinate ↔ fumarate + 2 H+ + 2 e- 
Also known as complex II its position is unique in energy metabolism since it provides a 
direct link between the tricarboxylic acid cycle and the respiratory chain and it is the only 
citric acid cycle enzyme that is membrane-bound. A highly conserved and similar complex 
is also found as part of the electron transport system in bacterial membranes; Bacillus 
subtilis and Escherichia coli have been very useful model systems for the study of the 
structure, function and assembly of this complex (Scheffler, 2008). 
The yeast SDH, like its mammalian counterpart, consists of four subunits (Sdh1p-Sdh4p in 
yeast, SdhA-SdhD in mammals) all encoded by the nuclear genome. 
The fundamental role of succinate-coenzyme Q reductase in the electron transfer chain of 
mitochondria makes it vital in most multicellular organisms. Removal of this enzyme from 
the genome has also been shown to be lethal at the embryonic stage in mice. As 
previously described, human mutations in genes encoding SDH subunits result in different 
diseases depending on which gene is mutated. In yeast SDH complex is essential for 
growth on respiratory carbon sources and disruption of any one of the four genes leads to 
the loss of SDH activity.  
The SDH structure (fig.1) consists of a hydrophilic head that protrudes into the matrix 
compartment and a hydrophobic tail that is embedded within the inner membrane. The 
hydrophilic head is composed of two subunits forming the catalytic core: SDH1 and SDH2 
in yeast and SDHA and SDHB in humans (for simplicity the yeast nomenclature will be 
used in this dissertation).  
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Figure 2.1. Model of the yeast SDH (Lemire and Oyedotun, 2002) 
The SDH1 gene encodes the flavoprotein containing subunit (Fp) and is located on 
chromosome XI. The FAD cofactor is covalently linked to Sdh1p through the HIS90 
residue. By mutating His-90 it was shown that covalent flavinylation was not required for 
SDH assembly to occur but that it was required for activity in succinate oxidation 
(Robinson and Lemire 1996a; Robinson and Lemire 1996b). Sdh1p with its 70kDa size is 
the largest polypeptide of complex II and is made as a precursor of 640 amino acids with 
a cleavable 28 amino acid N- terminal mitochondrial targeting sequence (Robinson and 
Lemire, 1992; Schülke et al., 1992; Bullis and Lemire, 1994). Loss of the SDH1 gene 
results in loss of SDH activity. Sdh1p contains also the binding site for succinate. 
Sdh2p, together with Sdh1p, is the other catalytic subunit also known as the iron-sulfur 
subunit (Ip). It contains three non heme Fe-S centers that mediate electron transfer to 
ubiquinone (Hägerhäll, 1997; Sun et al., 2005). These Fe/S centers consist of a 2Fe-2S 
center proximal to the FAD site, an adjacent 4Fe-4S center followed by a 3Fe-4S center 
(Yankovskaya, 2003; Sun et al., 2005). SDH2 encodes a polypeptide of 266 aminoacids 
(30kDa) with a mitochondrial targeting sequence of 20 aminoacids in length. The seven 
amino acids at the extreme C-terminus of the Sdh2p subunit containing a Lys-Lys 
sequence, are essential for activity and assembly (Schmidt et al., 1992). Sdh2p forms the 
interface between the catalytic domain and the membrane anchor domain of the complex 
(Rutter et al., 2010).  
In the catalytic dimer, as reviewed by Lemire and Oyedotun (2002), the absence of one 
subunit leads inevitably to the absence of the other suggesting that dimer formation is 
required for subunit stability (Lombardo and Scheffler, 1989; Robinson et al., 1991; 
Schmidt et al., 1992). However, subsequently studies which are discussed in the next 
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section opened up new perspectives about the stability of catalytic dimer. It is not clear 
whether the catalytic dimer could be stably formed and could exist in the absence of one 
or both of the membrane anchors. What is known in literature is that a yeast lacking one 
of the membrane anchor subunits shows a marked decrease in abundance of both of the 
hydrophilic subunits, Sdh1p and Sdh2p (Rutter et al., 2010) and this is in agreement with  
experiments performed in our laboratory (data not shown). 
From succinate the electrons flow to the FAD and sequentially through the 2Fe/2S, the 
4Fe/4S and the 3Fe/4S clusters and then pass into the membrane dimer (Lemire and 
Oyedotun, 2002).  
The membrane heterodimer is composed of two hydrophobic subunits, Sdh3p and Sdh4p, 
small peptides of 15kDa and 12-13kDa in mammals and 22kDa and 20kDa in yeast, 
respectively. Sequence analysis suggested that each subunit has three transmembrane 
segments along with a N-terminal domain extending into matrix where are localized the 
peptidase that cleaves this segment (Scheffler, 2008) (fig.2). 
 
Figure 2.2. Topological models of the membrane subunits.(A) Sdh3p model is indicated and the three 
transmembrane segments are referred to as I-III. (B) Sdh4p model with the three transmembrane segments 
IV-VI. (Lemire and Oyedotun, 2002) 
The membrane domain contains a bound heme b moiety and the binding sites for 
ubiquinone. Unlike the catalytic dimer, whose subunits exhibit remarkable evolutionary 
conservation in aminoacid sequences and in cofactor composition across species, the 
membrane anchor subunits vary considerably in subunit composition, subunit primary 
structure and in heme content (Hägerhäll and Hederstedt, 1996; Hägerhäll, 1997). The 
currently accepted model for the membrane dimer in all SDH enzymes has a core of four 
anti parallel helices and is based and supported by two crystal structures (Iverson et al., 
1999; Lancaster and Kröger, 2000) (Fig. 3). 
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Figure 2.3. Structural model of the membrane dimer (Lemire and Oyedotun, 2002) 
According to this model, Sdh3p contains three transmembrane helices numbered I-III 
while Sdh4 helices are numbered IV-VI. Transmembrane helices I,II, IV and V form an 
antiparallel helix bundle with helices III and IV dangling by the sides (Lemire and 
Oyedotun, 2002). Several observations with the yeast SDH suggested that 
transmembrane helices III or VI are not dispensable and that they may be necessary for 
providing rigidity or stability to the helix bundle. It has been proposed that helices III and 
VI may serve as hydrophobic zippers to stabilize the helix bundle (Hägerhäll and 
Hederstedt, 1996). Mutations that truncate Sdh3p or Sdh4p and remove helices III or VI 
severely impair respiratory growth and enzyme activity but do not lead to a complete loss 
of function (Oyedotun and Lemire, 1999; Oyedotun and Lemire, 2001). This suggests that 
helices III and VI are not required for catalysis but rather play roles in maintaining the 
structural integrity of the membrane dimer (Lemire and Oyedotun, 2002). 
Furthermore, Sdh4p contains a hydrophilic carboxylterminus of about 30 amino acids that 
extends into the intermembrane space which is absent in any other known SDH (Lemire 
and Oyedotun, 2002). The complete deletion of this region does not impair the respiratory 
growth and therefore it is not implied in the reduction of quinone. It rather stabilizes the 
helix bundle of the membrane dimer and affects the enzyme conformation. 
Two ubiquinone binding sites have been identified in SDH complex in mammals and in E. 
coli (Yankovskaya 2003; Sun et al., 2005). The high affinity ubiquinone site (Qp- 
proximal) lies on the matrix side of the IM and is formed by residues in Sdh2p, Sdh3p, 
Sdh4p. The Qp site lies within 7Å to the 3Fe-4S redox center and is the dominant 
ubiquinone site in yeast SDH (Lemire and Oyedotun, 2002; Silkin, 2007). The second low 
affinity ubiquinone site (Qd-distal) resides closer to the IMS side of the IM. Ubiquinone 
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reduction occurs in two stepwise single electron reactions, in contrast to the two electron 
reduction of FAD. The Qp site is effective in stabilizing the partially reduced semiquinone 
thereby permitting its full reduction to the ubiquinol and reducing the ROS generation 
(Yankovskaya, 2003). Protonation of ubiquinol is likely attained by a conserved Tyr 
residue in the Qp pocket (Silkin et al., 2007).  
The heme moiety, associated with Sdh3p and Sdh4p, is present in mammalian, yeast and 
E. coli SDHs. However the number of heme moieties and their redox properties vary in 
different species. This is consistent with the observation that membrane domain subunits 
show greater variability between SDHs than the highly conserved catalytic core domains 
(Hägerhäll, 1997). All SQRs characterized use two His residues for heme coordination 
(Hägerhäll, 1997; Lancaster and Kröger, 2000; Yankovskaya, 2003; Huang et al., 2005; 
Sun et al., 2005). The S. cerevisiae SDH is unusual because it uses a Cys residue as one 
of the heme axial ligands (Oyedotun et al., 2004). The two S.cerevisiae SDH heme axial 
ligands are: Sdh3p His-106 and Sdh4p Cys-78. Mutations in either of these ligands 
produce an enzyme that retains a significant content of heme but with altered spectral 
properties. In addition a heme free SDH of a S.cerevisiae mutant, without both axial 
ligands, is capable of an efficient assembly, of supporting growth on a non-fermentable 
carbon source and of succinate-dependent quinone reduction. Heme b therefore confers 
some structural stability to the enzyme but it is not an obligatory requirement for electron 
transfer from succinate to ubiquinone (Oyedotun et al., 2007). The significance and the 
role of the conserved heme moiety in eukaryotic SDHs is still unclear. The heme b is not 
necessary for the reduction of ubiquinone at the Qp site but it may mediate electron 
transfer to the distal Qd site (Rutter et al., 2010) and protect against oxidative damage by 
serving as electron sink (Yankovskaya, 2003). Baysal and colleagues identified mutations 
in the SDHD gene in individuals affected by paraganglioma and one of these mutations 
was the His102 residue substituted with a leucine (Baysal et al., 2000). They speculated 
that heme in SDH could play a role in oxygen sensing and in hypoxia response in 
paraganglioma tissues (Baysal et al., 2000). This histidine residue is located in an 
analogous position to His-71, a heme ligand in the E.coli SDHD (Vibat et al., 1998). 
Furthermore, in the Saccharomyces Genome Database (SGD) are present three intriguing 
entries. One is SDH1b, a gene located on chromosome IX and able to rescue only in 
multicopy the respiratory growth defect of Δsdh1 (Colby et al., 1998). This result 
suggested that SDH1b is unlikely to play an important role in mitochondrial respiration. 
The other two entries are represented by Sdh3p and Sdh4p paralogs. SDH3 paralog is 
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YMR118c and is located on chromosome XIII and its primary sequence is 57% identical to 
the SDH3 but its function is still unknown. SDH4 has two paralogs: YLR164w and 
YOR297c which are respectively 52% and 36% identical to Sdh4p. Noteworthy YLR164w 
contains the His -102 residue which is a potential axial ligand for heme (Lemire and 
Oyedotun, 2002).  
 
2.1.2. The SDH assembly 
Assembly of respiratory complexes is mediated by a large number of accessory proteins; 
despite complex II is the simplest respiratory complex and its structural and catalytic 
properties are well elucidated, little is known about the assembly mechanism. 
Intermediates, factors involved, timing as well as the mechanism of the addition of the 
various prosthetic groups are still poorly understood. 
Prior to 2009, only a couple of factors, Tcm62p and Flx1p, were known to be required for 
SDH assembly. But these factors are either not evolutionarily conserved or only act on 
SDH assembly indirectly (Rutter et al., 2010). In 2009 two new factors, Sdhaf1p (Sdh6p) 
and Sdh5p, have been described with dedicated and evolutionarily conserved roles in SDH 
assembly ( Ghezzi et al., 2009; Hao et al., 2009).  
TCM62: the gene encoding Tcm62p was originally identified in a screen for mutants 
specifically lacking SDH activity (Dibrov et al., 1998). Tcm62p is a 572 aminoacids 
(64kDa) polypeptide and has 16-17.3% sequence identities, distributed along the entire 
protein sequence, to E.coli  GROEL and yeast Hsp60 respectively (Dibrov et al., 1998). 
The Tcm62p amino terminus is in the mitochondrial matrix, whereas the carboxyl 
terminus is accessible from the intermembrane space. The Δtcm62 mutant had normal 
levels of components of complexes III, IV and V but undetectable Sdh2p. Overexpression 
of TCM62 results in the production of intramitochondrial inclusion bodies that also trap 
Sdh1p and Sdh2p subunits (Dibrov et al., 1998). According to this result, the authors 
proposed that Tcm62p functions as a chaperone in the assembly of yeast SDH. However, 
its role as well as its biochemical function are still unknown. Dibrov and colleagues 
speculated that Tcm62p might be involved in the formation or insertion of the clusters 
into apo- Sdh2p or, alternatively, might stabilize the holo-Sdh2p subunit before it forms a 
stable complex with the Sdh1p subunit (Dibrov et al., 1998). Afterwards Langer and 
colleagues showed that Tcm62p is required for thermostability of mitochondrial 
respiratory function and ensures mitochondrial gene expression at elevated temperatures 
preventing heat-aggregation of the ribosomal subunit Var1p (Langer et al., 2001). Var1p 
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is the only soluble protein encoded by the mitochondrial genome. At 24°C it was 
predominantly in the soluble fraction in both wild type and tcm62 strains. At 37°C 
however Var1p became insoluble in the tcm62 mutant but not in the wild type strain 
(Langer et al., 2001). Therefore, the authors suggested that Tcm62p could act more 
generally in the SDH assembly by supporting mitochondrial protein stability under stress 
(Rutter et al., 2010). 
FLX1: this gene was originally described by Tzagaloff and colleagues and is required for 
maintenance of a normal FAD/FMN ratio in mitochondria. However Flx1p role is still 
unclear and literature of the last six years did not clarify its function. It is clear that Flx1p 
is a mitochondrial transporter probably dedicated to flavin and it has been shown that in 
flx1 mutant the activities of SDH1 and LPD1, which contain FAD, were impaired (Rutter et 
al., 2010). Hao and colleagues in 2009 observed a very modest decrease of Sdh1 protein 
levels in the flx1 mutant but a complete loss of covalent FAD incorporation. 
Overexpression of SDH5 which is required for FAD incorporation, was able to partially 
restore the SDH1 - FAD covalent interaction that was lost in the flx1 mutant but not to 
rescue the growth defect on non fermentable carbon sources (Hao et al., 2009). 
Therefore the authors speculated that Flx1p is required for FAD incorporation into Sdh1p 
in a wild-type strain but it is also necessary for additional functions required for 
respiratory growth thus it being not specific for SDH complex (Hao et al., 2009).  
SDH5: it was found recently by Hao and colleagues in a screen for mutants incompetent 
to grow on glycerol, a non fermentable carbon source. They identified the yol071 mutant 
which had an OXPHOS growth defect and an undetectable SDH activity, while the activity 
of other TCA cycle enzymes and electron transport chain complexes were normal. The 
SDH complex seemed to be partially assembled in the absence of Yol071p but was 
unstable. Based on its requirement for SDH function, the authors renamed YOL071 as 
SDH5 (Hao et al., 2009). The key observation that pointed them toward the SDH complex 
came from purifying the Yol071 protein and discovering that it specifically copurified with 
Sdh1p (Rutter et al., 2010). In addition, they observed that Sdh5p was completely 
degraded in the sdh1 mutant supporting the idea of a Sdh1p-Sdh5p interaction. Moreover 
overexpression of SDH5 partially reduced the FAD incorporation defect of flx1 mutant. 
Finally and most directly, co-expression of SDH5 but not SDH2 with SDH1 in E. coli 
increased FAD incorporation (Rutter et al., 2010). The authors, therefore, proposed that 
Sdh5p is a dedicated SDH assembly factor required for the covalent insertion of FAD into 
the catalytic Sdh1p subunit. In addition, the discovery of SDH5 led to a further knowledge 
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about SDH assembly and in particular about the stability of Sdh1/Sdh2 dimer. Indeed if 
Lemire suggested that the absence of one catalytic subunit determined the absence of the 
other one, in 2009 Hao et al. observed a complete loss of Sdh2p in Δsdh1 yeast mutant 
but the presence of Sdh1p in Δsdh2 mutant (Hao et al., 2009). This result suggested that 
Sdh1p is required for the stability of Sdh2p but no viceversa. This can be explained with 
two hypothetical reasons: Sdh1p might be either in a pre assembled complex or be 
partially stabilized by other assembly factors or functional partners. For instance Sdh5p 
was absent in a Δsdh1 strain but was more abundant in a Δsdh2 mutant presumably due 
to enhanced Sdh1/Sdh5 complex formation in the absence of the major Sdh1p partner 
(Hao et al., 2009).  
SDHAF1/SDH6: it is the other assembly factor that together with Sdh5p is conserved 
and has a dedicated role in SDH assembly. In humans it’s known as SDHAF1 and in yeast 
as SDH6 (Ghezzi et al., 2009). The role of this protein in SDH assembly whose 
characterization is the subject of this dissertation is not clear. SDHAF1p presents a LYR 
tripeptide motif, a signature for proteins involved in the biogenesis of Fe/S clusters and 
for this reason it has been speculated that this protein could be important for the 
insertion or retention of the Fe-S centers within cII protein backbones.  
 
2.2. Iron-sulfur clusters biogenesis 
 
Iron sulfur clusters are important cofactors utilized by numerous proteins involved in 
several biological processes such as nucleotide biosynthesis and stability, protein 
translation, enzyme catalysis and mitochondrial metabolism (Rawat and Stemmler, 2011). 
Chemically the Fe-S clusters are made of ferrous (Fe2+) and/or ferric (Fe3+) iron and 
inorganic sulfide ions (S2-) linked together in specific structures and are usually integrated 
into proteins through coordination of the iron ions by cysteine or histidine residues or by 
alternative ligands such as Asp, Arg, Ser, CO, CN− and so on (Lill, 2009). The several 
structures in which they are organized ranging from the simplest rhombic [Fe2–S2] and 
cubane [Fe4–S4] forms up to [Fe8–S8] clusters, more complex form found in bacteria and 
archea (Brzóska et al., 2006). Fe-S clusters are therefore ubiquitous cofactors of 
numerous bacterial and eukaryotic proteins; they were discovered in the early 1960s and 
the first Fe-S proteins were found indeed in plant and bacterial ferredoxins so as in 
respiratory complexes I, II and III of bacteria and eukaryotic mitochondria (Lill, 2009). 
Since 1960 and for several decades chemists and biochemists thought that Fe-S clusters 
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assembled spontaneously on proteins. Only in the 1990s genetic and biochemical studies 
revealed that the biogenesis process was very complex and underlined the primary role of 
mitochondria in it (Scheffler, 2008). Thanks to the researches made in bacteria and in 
yeast, ample evidences of how this process was tightly regulated and coordinated were 
provided abolishing the idea of a spontaneous formation in vivo. What’s more, surprisingly 
in contrast to the chemical simplicity of Fe–S clusters, their biosynthesis in vivo appeared 
to be a complex but coordinated reaction (Lill, 2009). To date, the most of biogenesis 
components have been identified and the first insights into the mechanism of biogenesis 
have been obtained. In this section, the mechanism proposed for the assembly of yeast 
Fe-S will be discussed. Actually the studies in yeast allowed to obtain a large amount of 
details regarding eukaryotic mitochondrial Fe-S cluster assembly because of the high 
correlation and conservation between human and yeast systems and the facility of yeast 
biology (Rawat and Stemmler, 2011).  
As reviewed by Lill, the Fe/S clusters in proteins can serve for several functions that can 
be grouped into three categories namely electron transfer, enzyme catalysis and 
regulation (Lill, 2009). The most common function is in the redox processes: indeed this 
function is based on iron capability to formally switch between oxidative states +2 and 
+3. Thus Fe-S clusters can serve as excellent donors and acceptors of electrons and the 
redox potential depends mainly on the protein environment of the clusters. Considering 
that Fe-S proteins are present in mitochondria, cytosol and nucleus, this discussion will 
focus mainly on the mitochondrial Iron Sulfur Cluster (ISC) assembly since complexes I, II 
and III of the electron transfer chain are typical proteins involved in the redox reactions 
and contain Fe-S clusters.  
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Figure2.4. Model of yeast mitochondrial ISC assembly (step 1) and release(step 2) prior to the cluster being 
exported from the mitochondria (Rawat & Stemmler 2011). 
 
A schematic model of yeast ISC assembly is indicated in the fig.4: the mechanism which is 
very similar to that of bacteria, is made of two steps, the first based on the cluster 
synthesis on a scaffold protein and the second based on the transfer of the formed cluster 
to target apo proteins and its subsequent assembly into the polypeptide chain (Rawat and 
Stemmler, 2011). All these steps are tightly controlled and regulated since the free iron 
and sulfur ions are toxic for the yeast cells.  
Briefly, in the first step of Fe/S clusters assembly, the cysteine desulfurase Nfs1p 
functions as sulfur donor releasing the sulphur from cysteine to produce alanine and 
forms a stable complex with Isd11p. A persulfide intermediate is formed on the conserved 
cysteine residue of Nfs1p that can be transferred to Fe/S scaffold proteins. The source of 
iron is still unclear: it has been suggested that iron is imported into mitochondria in a 
membrane potential proton motive force driven fashion by Mrs3 and Mrs4 (mitoferrin in 
humans) which are inner membrane proteins (Mühlenhoff et al., 2003). Since it cannot be 
free in solution, iron is bound by specific proteins which functions as iron donors and 
mediates the iron delivery to the scaffold proteins. In particular Yfh1p seems to play a 
role in this mechanism since it functions as iron chaperone protein and binds iron, Nfs1-
Isd11 complex and the scaffold proteins (Zhang et al., 2006). In this step the ferredoxin 
reductase Arh1 and ferredoxin Yah1 are involved since they transfer electrons from NADH 
or NADPH, needed for the reduction of sulfane (S0 in cysteine) to sulfide (S2- Fe/S 
clusters). In this way the cluster is formed on the scaffold protein Isu1 or Isu2 which 
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contain conserved cysteine residues and bind Fe/S cluster in a labile manner suggesting 
that this cluster can be transferred to target proteins in the second step of biogenesis 
process (Lill, 2009; Rawat and Stemmler, 2011).  
In the step 2 the labile Fe/S clusters bound to the scaffold are transferred to the 
apoproteins which are converted from the apo form to the holo form (Lill, 2009). Several 
proteins are involved in this process and although the mechanism is not yet well defined, 
four proteins are thought to participate in this transfer: the chaperon protein of Hsp70 
ATPase family Sssq1, the DnaJ like co chaperone protein Jac1, the nucleotide exchange 
factor Mge1 and the monothiol glutaredoxin Grx5 (Rawat and Stemmler, 2011).  
All the aforementioned proteins plus other ancillary proteins are known as the ISC 
proteins and are required for the biogenesis of all mitochondrial Fe/S proteins. Most of 
these proteins are essential for viability of yeast and human cells. In yeast the depletion 
of these proteins results in growth defects or death. Several diseases in human are known 
to be associated with defects in Fe-S protein biogenesis components or Fe-S proteins. An 
example is given by the depletion of frataxin FXN gene (YFH1 in yeast), the putative iron 
donor for Fe-S cluster formation, which causes the Friedreich’s ataxia, a 
neurodegenerative inherited disease. Therefore it’s evident how the research about these 
proteins is pivotal since it can provide indications for development of therapeutic 
strategies in the treatment of Fe-S diseases (Lill, 2009). 
 
2.2.1. Fe-S clusters and SDH 
Within the respiratory chain complex I, II and III contain Fe-S clusters as cofactors. In 
particular, as previously described, the subunit II of SDH complex contains three Fe-S 
centers (2Fe/2S, 4Fe/4S and 3Fe/4S) and a heme b group. Therefore the correct 
biogenesis of these centers is necessary for a functional SDH enzyme. How the Fe/S are 
assembled and integrated in the complex II and which proteins are involved is not known. 
What is known is that in S.cerevisiae frataxin interacts physically with complex II 
providing electrons to ubiquinone (González-Cabo et al., 2005). Frataxin is a controversial 
protein conserved throughout eukaryotes which is thought to be an iron chaperone since 
it is able to bind iron and to promote the assembly of clusters on Nfs1/Isd11/Isu1 
scaffold. In S. cerevisiae the mutant lacking for frataxin shows a pleiotropic phenotype: 
up-regulation of the cellular iron uptake system and severe accumulation of iron in 
mitochondria (Stemmler et al., 2010). In addition this mutant exhibits an impairment of 
succinate dehydrogenase and aconitase activities, both enzymes which contains Fe-S 
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clusters. In 2005, Gonzales et al., showed the functional relation between SDH complex 
and YFH1 through genetic synthetic analysis. They therefore suggested a direct role of 
frataxin in regulating the entry of electrons toward the ETC. Moreover the authors 
identified a direct physic interaction between subunit 1 and 2 of SDH with Yfh1p 
speculating a direct participation of respiratory chain in the pathogenesis linked to the 
YFH1 absence (González-Cabo et al., 2005). 
ISD11 (Lyrm4 in humans) is another important gene linked to the Fe-S biogenesis, 
conserved from fungi to humans and is essential for cell viability. It was discovered by 
Wiedemann et al. in 2006. Isd11p participates to the first step of Fe-S biogenesis 
mechanism and binds the cysteine desulfurase Nfs1p and the scaffold protein. Its role is 
not well established yet. Yeast ISD11 conditional mutants identified by Wiedemann are 
characterized by a decrease of aconitase, succinate dehydrogenase (complex II) and 
cytochrome c reductase (complex III) activities (Wiedemann et al., 2006). Isd11p is 
characterized by the presence of LYR motif (LYK motif) which is a conserved tripeptide 
that seems to be important for the correct folding and function of the cysteine desulfurase 
Nfs1p (Adam et al., 2006; Shan et al., 2007; Wiedemann et al., 2006). The presence of 
Isd11p is therefore required for in vivo activity and stability of Nfs1p. 
 
2.3.Background: “SDHAF1, encoding a LYR complex-II specific assembly factor, is 
mutated in SDH-defective infantile leukoencephalopathy” Ghezzi et al., Nature Genetics, 
2009 
 
As previously mentioned the first bona fide SDH assembly factor which has been found is 
SDH6 (in yeast) or SDHAF1 (in humans) (Ghezzi et al., 2009). The authors have identified 
two family sets, one consisting of a large multiconsaguineous kindred of turkish origin 
with several affected children, the other composed of three affected children originating 
from a small village in an alpine valley of Lombardy in Italy. Two of the Italian affected 
children were second-degree cousins, one being born from first-degree cousin parents. 
Although they were not able to formally ascertain the consanguinity of the other parents 
and to connect the family of the third child with the other two, they assumed that all 
affected individuals had inherited by descent the same, presumably homozygous, 
mutation on the basis of virtually identical clinical presentations and common geographic 
origin.  
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Figure 2.5. Pedigrees of the Turkish and Italian family sets. Red numbers indicate the affected individuals 
who were studied. Allele genotyping symbols are +/+, for homozygous wild-type individuals, +/- for 
heterozygous individuals, -/- for homozygous mutant individuals. Black symbols indicate affected subjects. 
The dotted line indicates that the pedigree relation is suspected but not established (Ghezzi, 2009). 
 
The clinical features of the Turkish and Italian subjects were very similar and 
accompanied by a significant decrease in SDH activity and by a marked reduction of cII 
holoenzyme in muscle and fibroblasts.  
Symptoms consisted essentially of rapidly progressive psychomotor regression after a 6- 
to 11-month disease free interval with lack of speech development, followed by spastic 
quadriparesis and partial loss of postural control with dystonia. Brain magnetic resonance 
imaging showed severe leukodystrophic changes with sparing of the peripheral U-fibers 
and basal ganglia. Proton magnetic resonance spectroscopy revealed a decreased N-
acetylaspartate signal and abnormal peaks corresponding to accumulation of lactate and 
succinate in the white matter (Brockmann et al., 2002; Bugiani et al., 2006). Lactate and 
pyruvate were variably elevated in blood. The subjects underwent relative stabilization of 
their clinical conditions, with survival beyond the first decade of life in several cases, 
although their growth was consistently and severely impaired. Biochemical analysis of 
mitochondrial respiratory chain (MRC) complexes in muscle and fibroblasts showed a 
~20–30% residual activity of SDH and SCoQR, whereas the other MRC activities were 
normal. Protein blot analysis on one- and two-dimensional blue-native gel electrophoresis 
showed marked reduction of cII holoenzyme in muscle and fibroblasts. 
The gene encoding Sdhaf1p was identified through a genome wide linkage analysis using 
SNP array genotyping performed in the Turkish and Italian family. The authors identified 
a 1.2 Mb region on chromosome XIX which contained 42 annotations. A single 
anonymous entry in the region termed LOC644096, consisting in a single exon that 
predicted the translation of a 115 a.a putative protein of unknown function (Fig. 6).  
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Figure 2.6. Protein sequence of LOC644096. The LYR motifs are indicated in the box and the residues 
involved in pathological mutations, R55P and G57R, are in grey. 
This region contained also two homozygous missense mutations segregating with 
diseases: G57R in the Italian individuals and R55P in the Turkish ones and in addition the 
residues involved in these mutations are highly conserved across species (Fig.7). 
 
Figure 2.7. Multiple alignment of human SDHAF1 aminoacid sequence with orthologs form monkey (Macaca 
mulata), mouse (Mus musculus), fish (Tetraodon nigroviridis), fungi (Neurospora crassa), plant (Oryza 
sativa) and yeast (Saccharomyces cerevisiae), obtained with ClustalW . 
 
Within this aminoacid sequence, there are two LYR tripeptide motifs (Leu- Tyr- Arg) which 
are conserved and are present in the N-terminal region of several proteins. There are at 
least eight LYR-motif proteins (LYRM) in humans, including Sdhaf1p. Lyrm-4p is the 
human ortholog of yeast Isd11p, a protein that, as previously reported has an essential 
role in the mitochondrial biosynthesis of Fe-S centers. Indeed it forms a complex with the 
cysteine desulfurase Nfs1p and is required for formation of an Fe/S cluster on the Isu 
scaffold proteins (Wiedemann et al., 2006). Another example is represented by the two 
complex I subunits NDUFA6 (LYRM-6, 14kDa) and NDUFB9 (22kDa). Both contain the LYR 
motif but they have different functions (Cardol et al., 2004; Ye and Connor 2000). These 
data suggest that the LYR motif is a signature for protein involved in Fe-S metabolism. In 
particular, NDUFA6, NDUFB9 and probably SDHAF1 itself could be involved in the 
insertion or retention of the Fe-S centers within protein backbones of cI and cII. In S. 
cerevisiae the proteins that contain LYR motifs are Acn9p, Isd11p, Fmc1p, Sdhaf1p/Sdh6p 
and Mzm1p, recently identified (Atkinson et al., 2011).  
Because the trasfection of fibroblasts with the gene LOC644096 was not suitable to 
examine whether the disease-segregating missense mutations of SDHAF1 were indeed 
causing cII deficiency, the yeast S. cerevisiae was used as a model and a functional 
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analysis was performed. Yeast possesses a putative SDHAF1 ortholog, YDR379c-a an 
uncharacterized ORF of 239 bp localized on chromosome IV which encodes a 79 amino 
acid protein predicted to be localized in mitochondria. 
The alignment between LOC644096 and YDR379c-a (Fig.8) shows how the missense 
mutations are conserved, as well as the LYR motifs, although the identity between the 
two sequences is 21%. 
 
 
Figure 2.8. CLUSTAL-W Alignment between LOC644096 and YDR379c-a. In grey are pointed out the LYR 
motifs. The pathological residues in black.  
The YDR379C-A gene was disrupted in yeast by homologous recombination in BY4742 
background. The Δydr379c-a yeast strain was OXPHOS incompetent because of a 
profound and specific reduction of SDH activity ~ 65%, whereas complex IV activity was 
normal. The more severe phenotype was observed on acetate and this carbon source was 
chosen for the next experiments. Respiration in standard YNB medium containing 0.6% 
glucose was only slightly reduced and cytochrome spectra were normal (Fig.9). These 
results, taken together, suggested that YDR379c-a encoded a protein which was specific 
for complex II. 
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Figure 2.9. Respiratory complex activity and cytochromes spectra. Spot assay at 28°C on glucose, ethanol 
and acetate-based medium of Δydr379c-a and BY4742 wt. 
 
Transformation with the wild-type YDR379C-A restored OXPHOS growth of the Δydr379c-
a strain. Expression of wild-type human SDHAF1 failed to complement the yeast mutant 
strain, possibly because of the low similarity between yeast and human protein species 
(Fig.10). 
 
Figure 2.10. Functional complementation with LOC644096 in Δydr379c-a. 
Then yeast mutant alleles carrying the equivalent human mutations were created and 
introduced into the Δydr379c-a mutant. The mutant strains behaved like the null mutant 
and therefore the mutations had a pathological effect in yeast since they did not restore 
the growth on acetate (Fig.11). 
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Figure 2.11. Mutant alleles phenotype on acetate and glucose containing plates.  
Accordingly, SDH assay on mutant strains carrying the pathological mutations, indicated a 
specific reduction of the complex II activity. The other components of MRC were intact 
(Fig.12).  
 
Figure 2.12. SDH assay on mutant alleles R55P and G57R. 
Then the authors measured the apparent Km value for succinate and it was 1 mM in wild-
type and 1 mM in the null mutant, suggesting that defective SDH activity was caused by 
reduced number of enzyme units rather than by qualitative alterations of cII.  
Taken together, these results demonstrated that mutations in SDHAF1 caused an isolated 
cII defect associated with a specific leukoencephalopathic syndrome and the SDHAF1 
product was the first bona fide assembly factor specific to cII, as its loss determined 
severe reduction in the amount of the enzyme in both yeast and humans. In yeast this 
gene was renamed SDH6. 
Even though the experiments carried out in human and in yeast, have indicated that 
Sdh6p is required for assembly and full function of SDH complex the biochemical function 
of this protein remains to be elucidated. It could be speculated that SDH6 gene product 
interacts with the entire SDH complex or with a specific SDH subunit. The experimental 
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work described in this thesis has been focused on the biochemical and genetic 
characterization of SDH6.  
 
2.4. Results 
2.4.1. Characterization of Δsdh6 mutant 
 
SDH6 mutations do not affect mtDNA stability 
One of the classical analysis carried out on respiratory mutant yeast strains is the 
evaluation of mtDNA stability. It is known, indeed, that mutations in genes encoding for 
mitochondrial proteins can increase the mitochondrial mutability. S.cerevisiae has the 
unique property to produce cells with homoplasmic deleted mtDNA molecules, which are 
referred to as petites or rho− mutants. These mutants do not grow on respiratory carbon 
sources but they can grow on glucose thanks to the energy produced by fermentation.  
In order to evaluate whether the null mutation as well as the two pathological mutations 
of SDH6 were linked to an increased mtDNA instability a petite analysis was undertaken 
as described in the material and methods section. The petite mutants were counted after 
5 days of growth at 28°C. The values indicated below are the mean of five independent 
experiments. 
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Figure 2.13. Analysis of mtDNA stability. It is indicated the percentage of petite mutants in the several 
mutants. 
As shown in the graphic, the percentage of petites was similar in the strains analyzed 
indicating that neither the absence of Sdh6p nor its mutated forms affect the mtDNA 
stability. 
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Induction of SDH6 expression by oxidative carbon sources 
The SDH6 expression was analyzed in several carbon sources and determined by Reverse 
Transcription PCR (RT-PCR) (Weis et.al, 1992). This method allows to analyze gene 
expression in different conditions from different samples. It is based on a two steps 
process: the first step in which mRNAs are transformed in cDNA by reverse transcriptase 
and the second one in which the obtained cDNAs are specifically amplified with a common 
PCR reaction. 
Total RNA were extracted as described in the material and methods section from the wt 
strain BY4742 in exponential phase grown in YP medium added with: 
- 2%Glucose  
- 2%Ethanol  
- 2%Acetate  
- 2%Glycerol  
Then total RNA were quantified and prepared. 2µl of each cDNA samples were used for 
PCR reaction. The method was first set up with SDH4 gene. Indeed it is known that SDH 
genes are induced by ethanol and repressed by glucose. A first reaction of 30 cycles was 
performed in order to evaluate the effectiveness of the method. This reaction was 
performed using SDH4 primers which matched within the ORF region. This analysis was 
able to point out the induction by ethanol and repression by glucose (data not shown). 
We then analyzed SDH6 expression carrying out 25 cycles- PCR amplification by using 
YDRF and YDRR primers. As loading control TAF10 was used which encodes a subunit of 
TFIID involved in RNA polymerase transcription initiation. This gene was chosen as 
suitable internal control (reference gene) as suggested by literature (Teste et al., 2009).  
 
Figure 2.14. Expression of SDH6 in glucose and respiratory carbon sources. Transcripts of SHD6 were 
detected by RT-PCR of total RNA from BY4742 grown in YP added with the different carbon sources. RT-PCR 
control for all samples is represented by the amplification of TAF10. The cells were stocked at 1 OD.  
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The SDH6 expression pattern depicted in fig.14 showed a significant increase of SDH6 
expression in non fermentable sources especially in acetate. Furthermore, it was not 
repressed by glucose where its transcription was basal. 
 
Overexpression of ISD11 does not rescue the OXPHOS defect of Δsdh6 mutant 
As previously argued, the SDHAF1 human protein sequence contains two LYR motifs (Leu-
Tyr-Arg) and one of these motifs is fully shared with Sdh6p. The other one is still shared 
but the Tyr-residue is substituted with a Leu-residue. Ghezzi and co-authors speculated 
that Sdhaf1p could be involved in the insertion of Fe/S clusters within complex II due to 
the presence of this iron signature but no experiments were made in order to elucidate 
this putative role. In addition a BLASTP-based search of SDHFA1p in the Homo sapiens 
database showed a significant similarity with Lyrm-4, a protein involved in the iron-sulfur 
biogenesis whose ortholog in yeast is Isd11p. However, the BLASTP search with Sdh6p as 
query did not identify any significant protein.  
These two yeast proteins, Sdh6p and Isd11p, were aligned (fig.15). The similarity and 
identity values were respectively 59% and 16%. 
 
SDH6      MPKRLSGLQKEVLHLYRASIRTAHTKPKENQVNFVNYIHEEFG-KYRN-LPRKDFTTIEH 58 
ISD11     MPGFTAPTRRQVLSLYKEFIKNAN---QFNNYNFREYFLSKTRTTFRKNMNQQDPKVLMN 57 
          **  : :::** **: *:.*:  : *: ** :*: .:  .:*: : ::* ..: : 
 
SDH6      LLRVGNKKIATFS-HPELTNIH--------------- 79 
ISD11     LFKEAKNDLGVLKRQSVISQMYTFDRLVVEPLQGRKH 94 
          *:: .::.:..:. :. :::::         
 
Figure 2.15. Alignment between Sdh6p and Isd11p with CLUSTAL-W. 
It is worth mentioning that also Isd11p contains a LYK motif within its sequence, a 
signature similar to LYR motif where the Arg-residue is substituted with a Lys-residue. In 
addition ISD11 conditional mutants possess aconitase, succinate dehydrogenase (complex 
II) and cytochrome c reductase (complex III) activities diminished by 75-95% 
(Wiedemann et al., 2006).  
Since the presence of LYR/LYK motifs and the high protein sequence similarity we 
wondered whether ISD11 in multicopy could suppress the OXPHOS defect of Δsdh6 
mutant and viceversa whether SDH6 could rescue the mutant phenotype of Δisd11. 
The whole ISD11 ORF was amplified with PCR by using FISD11B and RISD11H primers. 
The amplified and purified fragment (~900 bp) was digested with BamHI and HindIII and 
then was ligated in YEplac195 vector. The recombinant construct was then sequenced.  
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Δsdh6 mutant was transformed with ISD11/YEplac195 and with the empty YEplac195 
with the protocol described in material and methods section. Three independent clones 
were used for spot assays on glucose, ethanol and acetate containing plates. Δsdh6/SDH6 
was also spotted as growth control. The mutant phenotypes were observed after 72h at 
28°C. 
 
Figure 2.16. Spot assay of three independent clones of Δsdh6/ISD11 performed on glucose, ethanol and 
acetate medium at 28°C. 
As depicted in fig.16 ISD11 in multicopy was not able to rescue the growth defect of 
Δsdh6 mutant. Therefore the two sequences which shared a sequence similarity did not 
share a similar function. Since ISD11 deletion is lethal a diploid ISD11/Δisd11 strain was 
transformed with wild-type SDH6 cloned in a multicopy vector (YEplac195/SDH6). The 
transformants, selected on minimal medium without uracile, were sporulated. The tetrad 
dissection was performed on glucose synthetic medium without uracile to ensure the 
presence of the plasmid. The viability of all the 4 spores was expected if SDH6 would 
have rescued the lethality of ISD11 deletion. The observation that only two of the four 
spores were able to germinate led us to conclude that SDH6 was not able to complement 
in multicopy the ISD11 deletion. An analogous experiment was done in order to evaluate 
the possible interaction between SDH6 and three other essential genes involved in the 
mitochondrial ISC biogenesis namely NFS1, JAC1 and YAH1. Also in this case we did not 
observe a complementation by SDH6. 
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Figure. 2.17. Tetrad analysis performed onNFS1, ISD11, JAC1 and YAH1 diploids (BY4743) transformed with 
SDH6/YEplac195. 
Overexpression of YFH1 does not rescue the OXPHOS defect of Δsdh6 mutant 
Another important gene of ISC complex is YFH1, encoding for the yeast frataxin homolog. 
Several physiological functions for frataxin in mitochondria have been proposed. Among 
these, the most relevant roles are related with the homeostasis of mitochondrial iron: in 
particular several works speculated that frataxin acts as an iron storage protein 
maintaining iron in a non toxic and bioavailable form (Adamec et al., 2000; Park et al., 
2003; Nichol et al., 2003). What’s more, literature data, as described in the previous 
section, suggested a closely relation between YFH1 and complex II. In particular Gonzales 
Cabo et al., through coimmunoprecipitation studies supported by genetic analysis 
identified a functional relationship between YFH1 and SDH subunit 1 and 2. Considering 
the primary role on Fe-S biogenesis and the putative role on the SDH complex, we 
wondered similarly to ISD11 whether YFH1 in multicopy could suppress the OXPHOS 
defect of Δsdh6 mutant.  
 
The whole YFH1 ORF was amplified by using YFH1FBh1 e YFH1RPs primers. The purified 
fragment (1200 bp) was digested with BamHI and PstI and then was cloned in YEplac195 
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vector. The sequenced construct and the empty vector were used to transform Δsdh6 
mutant. Spot assay were performed. 
 
 
 
 
Figure 2.18 . Spot assay at 28°C of three independent clones of Δsdh6/ISD11. 105, 104, 103, 102, 101 cells 
were plated on glucose and acetate containing plates after serial dilutions. 
As indicated in the fig.18, no growth rescue was observed. Further analysis are however 
necessary to exclude a putative role of Sdh6p with frataxin pathway. 
 
Overexpression of SDH5 and TCM62 does not rescue the OXPHOS growth 
defect of Δsdh6 mutant 
To gain insight into the function of SDH6, we analyzed if the other SDH assembly factors, 
SDH5 and TCM62, could in multicopy rescue the growth defective phenotype of sdh6 
mutant and viceversa. Therefore both genes were cloned in YEplac195. SDH5 was 
amplified with PCR by using FSDH5B and RSDH5H primers and the purified PCR product 
was digested with BamHI and HindIII; subsequently the 1000 bp fragment was cloned in 
YEplac195. As regards TCM62, the ORF region was amplified by using FTCME and RTCMP 
primers and the amplified fragment (~2700 bp) was digested with EcoRI and PstI and 
cloned in YEplac195. 
Both the constructs were used to transform the Δsdh6 mutant. Then a spot assay analysis 
with the transformant clones was carried out and the Δsdh6/SDH6 was plated as growth 
control. 
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Figure 2.19. Spot assays at 28°C of Δsdh6/SDH5 and Δsdh6/TCM62. 105, 104, 103, 102, cells were plated on 
glucose and acetate containing plates after serial dilutions. The growth was observed after 72h at 28°C. 
On acetate where the Δsdh6 phenotype is more severe, neither SDH5 norTCM62 were 
able to rescue the respiratory growth defect of the mutant. These results suggested that 
Sdh6p had a different function in the SDH assembly. The same results were obtained 
overexpressing SDH6 in Δsdh5 and Δtcm62 mutants (data not shown). The SDH6 ORF 
was amplified by PCR using FY379 and RY379 primers, digested with EcoRI and PstI and 
cloned both in pFL38 and YEplac195 plasmids. This result further indicated that the three 
SDH assembly factors were not interchangeable. 
 
Overexpression of the four SDH subunits does not enhance enzyme activity in 
the absence of Sdh6 protein 
In order to investigate the role of Sdh6p, we wondered if overexpression of the four SDH 
subunits could increase the SDH activity in Δsdh6 mutant. Actually the aim was to 
evaluate the possibility to increase SDH activity to 100% and to analyze in this case the 
sdh6 phenotype and eventually the state of complex. Therefore SDH1 and SDH2 were 
cloned in YEplac181 and SDH3 and SDH4 in YEplac195. The Δsdh6 strain was 
transformed with both the plasmids and mitochondria were isolated as described in 
material and methods section. The SDH assay was performed on the Δsdh6 transformed 
both with the four SDH subunits and with the two empty vectors.  
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Figure 2.20. SDH assay of BY4742/SDH, BY4742/EMPTY,  Δsdh6/EMPTY and  Δsdh6/SDH: the results are the 
average of three independent experiments. 
As indicated in the histogram (Fig.20), only in BY4742 there was an increase of SDH 
activity from 100% (BY4742/EMPTY) to 150% due to the four overexpressed subunits 
(BY4742/SDH). No differences between Δsdh6/EMPTY and Δsdh6/SDH were observed so 
the presence of all SDH subunits was not sufficient to increase SDH activity. This result 
was very intriguing and not obvious. It underlined that Sdh6p was the limiting factor of 
complex II assembly. Indeed, even if the four SDH subunits were present and abundant 
in the cell, only in presence of a functional Sdh6p assembly factor the complex could be 
assembled showing an extra-enzymatic activity as occurred in wt strain. In addition, spot 
assays of Δsdh6/SDH and Δsdh6/empty  were performed on 2%ethanol. 
Parallel to the activity, neither the Δsdh6 phenotype was rescued on respiratory carbon 
source (Fig.21). 
 
Figure 2.21. Spot assays of  Δsdh6/SDH, Δsdh6/EMPTY, BY4742/SDH at 28°C. 105, 104, 103, 102, 101 cells 
were plated on glucose and ethanol containing plates after serial dilutions. The growth was observed after 1 
week at 28°C. 
Even the wt strain showed a slowly growth on non fermentable carbon sources 
suggesting that all SDH subunits overexpressed at the same time affected negatively the 
cell, probably causing an energetic cell imbalance.  
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In addition we overexpressed the four SDH subunits in the Δsdh5 mutant, the other 
specific SDH assembly factor. However, it is worth mentioning that unlike sdh6 mutant, 
Δsdh5 is characterized by a complete loss of SDH activity. Again we did not observe an 
increase of SDH activity or any phenotype rescue on respiratory carbon sources (Fig.22 
and fig.23)  
 
Figure 2.22. SDH assay of BY4741/SDH, BY4741/EMPTY, Δsdh5/EMPTY and Δsdh5/SDH: the results are the 
average of three independent experiments. 
 
 
Figure 2.23. Spot assays of Δsdh5/SDH, Δsdh5/EMPTY, BY4742/SDH at 28°C. 105, 104, 103, 102, 101 cells 
were plated on glucose and ethanol containing plates after serial dilutions. The growth was observed after 1 
week at 28°C. 
Once more this result highlights the involvement of Sdh6p in SDH assembly process: this 
protein is indeed necessary to ensure a fully assembled and functional complex II and its 
role could not be bypassed by increasing the number of SDH subunits in the cell.  
 
Steady state levels of SDH subunits are decreased in Δsdh6 mutant 
As previously demonstrated Δsdh6 showed a 70% decrease in SDH activity and a Km 
value for succinate similar in wild type and in the null mutant. This result indicates that 
the reduced SDH activity could be due to a reduced complex II amount rather than a 
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qualitative alteration of it. Furthermore, the overexpression of four SDH subunits in the 
Δsdh6 mutant did not restore the SDH activity supporting the idea of a quantitative 
problem of complex II in this strain. Therefore, SDS-PAGE and 2D-BNGE were performed 
to evaluate the SDH assembly state in the null mutant. Mitochondria were extracted as 
described in materials and methods section and quantified with Bradford. 30µg and 60 µg 
of mitochondria were separated on a 15% polyacrylamide gel and transferred to 
nitrocellulose membranes.  
Western Blots with Anti-Sdh1p and Anti-Sdh2p antibodies were performed and the 
immunoblot for Atp4 subunit (complex V) was used to show equivalent protein loads per 
lane (Fig.24) 
 
Figure 2.24. SDS-PAGE Western Blot of Δsdh6 and BY4742 mitochondria. Two different concentrations of 
each sample were loaded with Laemmli sample buffer 1X. 
In agreement with the reduction of SDH activity, the Sdh1p and Sdh2p levels were 
significantly decreased in the Δsdh6 mutant. To evaluate the complex II state of 
assembly, a 2D-BNGE was then performed. The anti-Sdh2p and anti-Atp4p antibodies 
were used for the immunoblot (Fig.25). 
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Figure 2.25. 2D-BNGE Western Blot of Δsdh6 and BY4742 mitochondria. 150 µg of mitochondria were 
solubilized with 1% lauryl maltoside and loaded on a gradient gel. Then each lane was excised and treated 
for 1 h at room temperature with 1% SDS and 1% b-mercaptoethanol and then run through a 16.5% 
tricine-SDS–polyacrylamide gel. 
 
 
1% Lauryl maltoside extracts of mitochondria isolated from Δsdh6 cells and separated on 
2D-BNGE showed: 
 a fully assembled complex II (~30kDa) 
 a decreased amount of complex II. 
In the first dimension, the hybridization Sdh2p signal was not detectable probably 
because of the Sdh2p folding which did not allow the antibody binding. 
These results definitely demonstrated that the defective SDH activity is caused by a 
reduced number of enzyme units rather than by qualitative alterations of complex II and 
underlined the Sdh6p specific role in SDH assembly. This specificity is due to the fact that 
the other respiratory complexes are intact both in human and in yeast.  
 
2.4.2. Characterization of Sdh6p 
The results previously obtained analyzing HeLa cell fractions expressing SDHAF1HA 
indicated that Sdhaf1p is localized in the mitochondrial matrix and that is not physically 
associated with cII in vivo (Ghezzi et al., 2009). In order to assess these results a 
biochemical characterization of Sdh6p protein was performed in yeast. First SDH6 was 
tagged with HA tag or HIS tag and then its localization was determined. The proteinase K 
assay was carried out to establish whether Sdh6p was inaccessible to proteinase K action 
being inside the mitochondria and then a 2D-BNGE electrophoresis was performed to 
evaluate where Sdh6p-HA localized. 
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Construction of SDH6 TAG  
The SDH6 ORF was amplified with primers FY379 and PRYDRHA to obtain the SDH6-HA 
construct which contained the SDH6 promoter region and the tag tail a 3’ terminus. The 
primers FY379 and RYDRHIS were used to obtain the same construct with the His tag tail 
at 3’ terminus.  
The amplified regions were digested with EcoRI and PstI and cloned in pFL38 and 
YEplac195.  
 
Figure 2.26. Strategy scheme of SDH6-tag construction 
Subsequently, the endogenous SDH6 terminator was amplified in order to increase the 
efficiency of the recombinant protein translation. The terminator region of Sdh6 was 
amplified by PCR using YDRFPTER and YDRRHTER primers. The amplified terminator 
fragment (300 bp) was digested with PstI and HindIII. So it was ligated to the SDH6-TAG 
and then the whole constructs were cloned in the plasmids pFL38 and YEplac195. 
The recombinant constructs obtained were used to transform the Δsdh6 strain. Neither 
HA tag nor HIS tag affected the Sdh6p expression (data not shown). However, it was 
shown with a SDS PAGE that the terminator region absence affected negatively the SDH6 
expression, maybe because mRNA was less stable and therefore the protein translation 
was less efficient. 3 different mitochondria concentrations of Sdh6p-HA-TER and Sdh6p-
HA were loaded and immunodecorated with α-HA antibody. The Western Blot indicated 
that the terminator region was necessary for the SDH6 efficient expression and therefore 
all the experiments were carried out with the strains expressing the plasmids containing 
it.  
 
 
Figure 2.27. Western Blot SDS PAGE of Sdh6p-HA mitochondria with or without the terminator region.  
3 different concentrations of mitochondria were loaded and solubilized with Laemmli buffer 1X. 
 
  
SDH6HA-TER SDH6HA 
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Proteinase K assay treatment 
The proteinase K assay is a treatment that may indicate in which mitochondrial 
subcompartment a protein resides. Indeed it degrades the mitochondrial outer membrane 
and what is contained inside mitochondria is protected by its action. Therefore isolated 
mitochondria were treated as described in material and methods section and resolved 
with SDS-PAGE. Also the Post Mitochondrial Fraction (PMS) was loaded as control 
resembling the cytosol. 
 
Figure 2.28. Proteinase K assay after1h of treatment(+/-). Also the post mitochondrial fraction (PMS) was 
loaded. 
The western blot with anti-HA indicated that proteinase K did not affect Sdh6p-Ha signal 
(fig.28). Therefore Sdh6p is localized inside mitochondria, confirming what seen in HeLA 
cells by Ghezzi et al.,. Indeed there are no significant differences between the fraction 
treated or not with Proteinase K underling how this protein resides inside mitochondria. 
However a lower signal intensity of Sdh6p-HA was present in the PMS fraction but this 
was due to some contamination of mitochondria in the cytosol fraction as indicated by 
Western Blot anti COXIII (data not shown). 
 
Sdh6pHA is not associated to SDH complex nor to other molecular complexes 
In order to determine whether Sdh6p associated with any higher molecular weight 
complexes such as fully assembled complex II or cII assembly intermediates and to 
exclude the possibility that Sdh6p is actually an unidentified subunit of the mature 
complex, mitochondria isolated from the strain expressing Sdh6p-HA were analysed in 2D-
BNGE. For Western blot analysis antibodies directed against the HA epitope and Sdh2p 
subunit were utilized. A single signal for both Sdh6p-HA and Sdh2p was detected in Δsdh6 
transformed with pFL38-SDH6-HA as depicted in the fig. 29. Sdh6p showed a mobility of 
12 kDa in the second dimension. This corresponded to the expected molecular weight of a 
monomeric molecule. 
SDH6 
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Figure 2.29. 2D-BNGE Western Blot of Sdh6p-HA mitochondria. 150 µg of mitochondria were solubilized with 
1% lauryl maltoside and loaded on a gradient gel. Then the lane was excised and treated for 1 h at room 
temperature with 1% SDS and 1% b-mercaptoethanol and then run through a 16.5% tricine-SDS–
polyacrylamide gel. 
These results indicated that Sdh6p was not physically associated with CII in vivo nor took 
part, at least stably, in other complexes in these analysis conditions accordingly with what 
seen in HeLa-cells by Ghezzi. 
 
Sdh1p and Sdh2p are not Sdh6p interactors 
Despite the 2D-BNGE showed no Sdh6p-Sdh2p interaction, these results were not 
sufficient to exclude a possible interaction of Sdh6p with the SDH subunits. Therefore an 
affinity purification was carried out exploiting the interaction between His6x residues and 
Ni-Nta agarose beads. The whole SDH6 ORF was expressed with a tail of six histidine 
residues before the stop codon, as previously described, and was able to complement the  
Δsdh6 null mutant (data not shown). Once obtained the strain, mitochondria were 
isolated and an affinity purification was performed as described in the material and 
methods section. However, in the Western Blot of final eluate no Sdh6p-His signal was 
detected. This result maybe was due to the extraction conditions suggested by the 
protocol, which indicated a solubilisation buffer containing 3% digitonin. Therefore the 
mildest extraction conditions for Sdh6p-His6x were identified: three digitonin 
concentrations were assayed included the 3% digitonin. As indicated in the fig.30 (A) the 
best condition for the Sdh6p extraction was 0.75% digitonin which was enough to 
solubilise at least the 50% of protein (the pellet is the fraction not solubilised). Strikingly 
with 3% digitonin the Sdh6p-His signal was almost completely loss in the supernatant and 
this could explain the absence of the signal observed in the first purification. In addition, 
to improve the solubility efficiency, in the extraction buffer was added NaCl either 50 mM 
and 150 mM (fig.30 B). This latter concentration was the best to extract completely the 
High MW Low MW
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∆sdh6/SDH6HA
SDH2 SDH6HA
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protein in the supernatant although it was not recommended since it could abolish 
probably ionic interactions in a dose dependent manner. 
 
Figure 2.30. Sdh6p-HIS extracting conditions: SDS PAGE 12% Western Blot.  
Therefore a first purification was carried using the mildest condition (digitonin 0.75%) on 
Δsdh6 transformed with pFL38-SDH6-HIS6X. The final eluate was resolved with SDS-
PAGE 12% and visualized by immunoblot with antibodies against Sdh2 and His. The 
supernatant and pellet fractions were also loaded as extraction controls (fig.31). 
 
Figure 2.31. SDS-PAGE 12% Western Blot on final eluate of Δsdh6 transformed with pFL38-SDH6-HIS6X and 
immunodecorated with α-Sdh2 and α-His. Supernatant, pellet and flow through fractions were loaded as 
controls. 
The Western Blot indicated that α-His hybridization signal was present both in the final 
eluate and in the supernatant suggesting that the extraction was efficient. However a 
Sdh6p-His signal was detected also in the flow through fraction indicating that the binding 
Sdh6-His/beads was not optimal. Furthermore α-Sdh2 signal was not detected in the final 
eluate. The strong Sdh2p signal in pellet might indicate that the optimal Sdh2p extraction 
condition was not the same of Sdh6p.  
To identify the Sdh1p signal a SDS-PAGE 15% was performed since Sdh1p was 70kDa. 
The western blot is reported below (fig.32). 
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Figure 2.32. Western Blot SDS-PAGE 15% on final eluate of Δsdh6 transformed with pFL38-SDH6-HIS6X and 
immunodecorated with α-Sdh1. Supernatant, pellet and flow through fractions were loaded as controls. 
The Western Blot indicated that also Sdh1p was not present in the final eluate. This 
suggested that neither Sdh1p nor Sdh2p interact with Sdh6p in these conditions. 
In addition, in order to improve the extraction of Sdh6p, 150 mM NaCl was added to the 
solubilisation buffer and the purification was carried out. No changes were detected in the 
Western Blots performed (data not shown).  
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This first part of the results pointed out a fundamental role of Sdh6p in the SDH 
assembly. In particular these results suggested that Sdh6p absence determines a marked 
decrease of SDH activity which is in agreement with the decreased amount of SDH 
complex, seen in BN-PAGE. Moreover, Sdh6p is a rate limiting factor of SDH assembly: 
indeed even if all four SDH subunits were overexpressed at the same time the SDH 
activity could not be restored in the mutant suggesting a pivotal role of Sdh6p in cII 
assembly. 
Both the presence of a LYR motif in the Sdh6 protein and the sequence similarity with 
Isd11p prompted us to investigate the putative role of Sdh6p in the insertion of Fe-S 
clusters on cII backbone by overexpressing ISD11 in the sdh6 mutant. Also frataxin was 
expressed in multicopy in the null mutant on the basis of the experimental evidence 
reported in literature. 
Although from obtained results no indications have come out about a role of Sdh6p linked 
to the Fe-S clusters metabolism we could not exclude a role of Sdh6p in the iron 
metabolism. 
The experiments described so far excluded any direct interaction between Sdh6p and SDH 
subunits suggesting that Sdh6p is not part of complex II. However these results still did 
not shed light on the action mechanism of Sdh6p. Therefore in order to gain more 
information about SDH6 role we performed a search for multicopy suppressors. 
The second part of the thesis will be focused on the results obtained with the search for 
multicopy suppressors and the experiments undertaken: after a brief introduction on the 
iron metabolism in yeast, the experiments performed will be the object of discussion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter III: 
An additional role of SDH6 besides SDH assembly 
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3.1. Iron metabolism in yeast 
 
Iron is essential for all organisms: it is an essential cofactor for respiration, DNA synthesis 
and repair, ribosome biogenesis and metabolite biosynthesis (Ihrig et al., 2010). Although 
iron is highly abundant its bio availability is difficult: the soluble form Fe2+ spontaneously 
auto-oxidizes to Fe3+ which is insoluble in water at neutral pH (Kosman 2003). On the 
other hand iron may be toxic at higher concentrations within the cell because it is the 
major source of reactive oxygen species. Therefore specific mechanisms for iron uptake, 
storage and trafficking have been developed in the cells, in order to avoid the presence of 
free iron forms that would be dangerous. 
 
Figure 3.1. Iron homeostasis in S. cerevisiae. Transporters are in red, oxidases in blue, transcription factors 
in yellow, reductases in olive (Bleackley & Macgillivray, 2011) 
 
In yeast S. cerevisiae the iron uptake occurs through the action of specific transporters 
that channel Fe2+ or Fe3+ within the cell (fig. 1): Fet4p and Smf1p are able to bind only 
the Fe2+ form which is produced by the action of Fre1/Fre2 reductases. This action can be 
bypassed by the high affinity iron transport system consisting in Fet3/Ftr1 complex which 
is induced in iron limiting conditions by Aft1p, transcription factor which regulates the 
expression of iron regulon (Yamaguchi-Iwai et al., 1995). Fet3p is a oxidoreductase which 
oxidizes Fe2+ in Fe3+ and transports it to Ftr1p. This iron transporter is able to bind only 
the Fe3+ produced from the activity of Fet3p in a process known as iron channeling (Kwok 
et al., 2006). Siderophore are another iron uptake mechanism which is independent by 
the activity of Fre reductases bound to the membrane (Bleackley and Macgillivray, 2011). 
These are small organic molecules able to bind Fe3+ secreted in iron limiting conditions by 
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several organisms except S.cerevisiae which does not produce them. However 
S.cerevisiae expresses siderophore transporters namely Arn1p, Arn2p, Arn3p, Arn4p and 
siderophore binding/uptake proteins Fit1p, Fit2p, Fit3p belonging to the family of cell wall 
mannoproteins (Protchenko et al., 2001).  
In iron starvation conditions, S. cerevisiae upregulates the iron regulon which depends on 
the Aft1p transcription factors. In this conditions it is translocated into the nucleus where 
activates the transcription of more than 20 genes that are required for increasing cellular 
iron content (Yamaguchi-Iwai et al., 1995; Rutherford et al., 2001; Rutherford et al., 
2003; Shakoury-Elizeh et al., 2004; Courel et al., 2005). This translocation seems to be 
dependent on the Fe/S clusters present in the cell.  
A second iron responsive transcription factors is Aft2p which exhibits a partial overlapping 
function with Aft1p in activating genes in response to the iron starvation (Blaiseau et al., 
2001; Rutherford et al., 2001; Rutherford et al., 2003; Courel et al., 2005; Rutherford et 
al., 2005). Indeed these two transcription factor possess two different roles in the 
transcriptional regulation of iron regulon with Aft2p playing a larger role in the regulation 
of genes involved in vacuolar and mitochondrial iron homeostasis (Courel et al., 2005; 
Rawat and Stemmler, 2011). 
Within the mitochondria both the synthesis of heme and Fe/S clusters occurs and this 
makes the organelle a major site of intracellular iron metabolism. The iron uptake in the 
mitochondria is mediated by two homologous membrane transporters, Mrs3/Mrs4p, also 
known as mitoferrin in humans (Mühlenhoff et al., 2003). Once inside the mitochondria, 
iron is bound presumably by frataxin that shuttles iron where it is required. In the 
absence of frataxin iron accumulates forming inorganic precipitate and generates reactive 
oxygen species (Rawat and Stemmler 2011). Another important site for iron homeostasis 
is the vacuole. 
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3.2. Results 
3.2.1. Identification of multicopy suppressors of Δsdh6 mutant 
As previously mentioned the experiments so far described did not elucidate the action 
mechanism of SDH6. To gain further insight into the functional role of SDH6 an exhaustive 
high copy suppressors screen of the ∆sdh6 OXPHOS defect was performed. The search 
for multicopy suppressors is a genetic method very useful to identify genes that could 
functionally substitute in multicopy specific gene mutations. This approach allows to 
identify interactions between gene products and can reveal the existence of metabolic or 
cellular connections. 
Therefore sdh6 null mutant was transformed with the genomic library constructed in 
pSEY8 vector (kindly provided by Dott. Schatz, Basel) and after selection of Ura+ 
transformants the clones able to grow on YNB-acetate (YNBA) at 28°C were identified. In 
this screen acetate, instead of ethanol or glycerol, was utilized because in this condition 
the phenotype of Δsdh6 is more severe, condition that favours the search for multicopy 
suppressors. 
In order to exclude the presence of the wild type gene in the recombinant plasmid, a 
colony PCR was performed. From suppressor colonies that did not contain SDH6 in the 
vector DNA was recovered: restriction analysis with EcoRI-HindIII indicated that plasmids 
contained different fragments of yeast genomic DNA in addition to the 6000 bp pSEY8 
band. An example of these different restriction patterns is reported below (fig. 2).  
 
 
Figure 3.2.. Six different restriction patterns: the upper bands are the plasmid pSEY8 and the other bands 
represent the digested fragments corresponding to genomic yeast DNA.  
Genomic inserts in each plasmid were sequenced at both ends and compared with the S. 
cerevisiae genome using NCBI BLAST search. The results obtained indicated that only two 
genes were able to rescue the Δsdh6 OXPHOS growth phenotype: here below an example 
of the output of the sequence analysis is represented: 
 7    18      22     47     83      106  M 
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Clone 86: the size of the fragment was 3Kb, it was localized on chromosome XIII and 
contained the whole ORF YAP1 and a part of YML006C gene (fig.3). Therefore it was 
probable that YAP1 was responsible for the multicopy suppression.  
 
Figure 3.3. BLASTN of digested fragments 
 
Clone 47: the identified fragment was localized on chromosome IV, was of 2,5 Kb and 
contained the whole ORF YAP2. Other genes were present but not completely and 
therefore the multicopy suppression was due to YAP2 presence (Fig.4) 
 
 
Figure 3.4.BLASTN of digested fragments. 
The two genes identified were YAP1 and YAP2 encoding two transcription factors involved 
in stress response and in many other cellular processes and whose description will be 
discussed later. In order to evaluate whether these two genes were responsible for the 
rescue of OXPHOS phenotype, they were cloned in the multicopy plasmid YEplac195. 
 
Subcloning of YAP1 and YAP2 in YEplac195  
The whole YAP1 ORF was amplified by using EYAP1F and HYAP1R primers and the 
amplified fragment (~2500 bp) was digested with EcoRI and HindIII and cloned in 
YEplac195. The same was made for YAP2 (1700 bp) by using BYAP2F and PSYAP2R 
primers and digested with BamHI and PstI. 
Following the purification and sequencing of the recombinant constructs, YAP1/YEplac195 
and YAP2/YEplac195 were used to transform Δsdh6. Also the empty YEplac195 was used 
to transform Δsdh6 as control. 3 independent clones transformed with each construct 
were used for spot assay on acetate carbon source. As growth controls Δsdh6/pFL38 and  
Δsdh6/SDH6 were also spotted. 
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Figure 3.5. Spot assays at 28°C. 105, 104, 103, 102, 101cells of each clone were plated on glucose and acetate 
containing plates after serial dilutions. The growth was observed after 72h at 28°C.  
Both YAP1 and YAP2 were able to rescue the OXPHOS defect on YNBA suggesting that 
these genes were responsible for the multicopy suppression. However, after 1 week 
growth at 28°C the Δsdh6 phenotypes due to the YAP1 or YAP2 presence were different. 
The rescue dependent on YAP1 was greater than the one due to YAP2. Indeed, 
comparing the ability of Δsdh6 to grow on acetate-based medium, it is evident that YAP1 
allowed a growth more similar to wt than Δsdh6 transformed with YAP2. These results 
indicate that YAP1 and YAP2 play different roles in the cells activating the transcription of 
different target genes whose effects in Δsdh6 result in a different growth. 
 
3.2.2. The transcription factors Yap1 and Yap2: their role in the cell. 
These two genes belong to the YAP family, Yeast Activator Protein, a family of b-ZIP 
proteins involved in several cellular processes. As recently reviewed by Pousada et al., the 
YAP family consists of eight proteins with sequence similarity to the conventional yeast 
AP-1, Gcn4, at the DNA binding-domain (Rodrigues-Pousada et al., 2010). However each 
member of this family has key residues within the sequences that give them distinct DNA 
binding properties. The characteristics that distinguish the members of Yap family from 
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Gcn4 family are the aminoacids involved in the DNA binding. Below is reported a scheme 
of the structural features of the Yap family. In general, they have a cysteine-rich domain 
(n-CRD or c-CRD depending it is at C- or N- terminus or both) and a Nuclear Export Signal 
(NES) (fig.6)  
 
Figura 3.6. Structural features of the Yap family. In the upper part of the figure, the sequences of the eight 
Yap bZIP domains are compared with the equivalent region of Gcn4 ( Rodrigues-Pousada et al., 2010)1. 
The cysteine rich domain (CRD) guarantees the nuclear retention of the transcription 
factor such as Yap1p (Kuge et al., 1997). When this region is removed, Yap1p is 
constitutively localized in nucleus in an active form. This occurs because an intramolecular 
disulphide bond forms on Cys residues of these domains that compromise the binding of 
the exportin Crm1p (also known as Xpo1) to the NES (Yan et al., 1998).  
The different DNA binding abilities confer to each Yap protein a specific role in cellular 
processes such as oxidative stress, cadmium stress, iron metabolism and others. A 
general scheme of these roles is reported in fig.7 . 
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Figure 3.7. Potential interplay between members of the Yap family (Rodrigues-Pousada et al., 2010) 
Yap1 was the first member of the YAP family to be described and was identified by its 
ability to bind and activate the SV-40 AP-1 recognition element (ARE: TGACTAA), 
functional homologue of the human c-jun oncogene (Moye-Rowley et al., 1989). What’s 
more, YAP1 was found in a multicopy suppressors screen because it conferred resistance 
to the iron chelators 1,10-phenantroline and 1-nitroso-2-naphtol (Bossier et al., 1993). In 
addition, also YAP2 was able to confer resistance to 1,10 phenantroline in the 
aforementioned screen (Bossier et al., 1993). Like Yap1, Yap2 is related to the 
mammalian proto-oncoproteins c-jun (Moye-Rowley et al., 1989; Bossier et al., 1993; Wu 
et al., 1993). Several phenotypes associated with the disruption of YAP1 and YAP2 have 
been described. These mutants are for example more sensitive to cadmium, zinc or to 
oxidative agents (Wu et al., 1993; Schnell and Entian, 1991).  
Taking into account the several cellular roles of Yap factors, the identification of these two 
genes in our multicopy suppressors screen was very intriguing. Since the two genes YAP1 
and YAP2 were both able to rescue the OXPHOS growth defect of sdh6 null mutant we 
wondered whether the phenotype suppression was accompanied by an increase of SDH 
activity. To answer to this question the SDH assay was carried out.  
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Multicopy suppressors YAP1 and YAP2 are able to rescue the growth of Δsdh6 
but not to increase SDH activity 
 
Figure 3.8. SDH assay on transformant strains Δsdh6/YAP1 and Δsdh6/YAP2. Δsdh6/pFL38 and Δsdh6/SDH6 
were used as controls. 
The SDH activity was measured in Δsdh6/YAP1 and Δsdh6/YAP2 transformant strains. The 
assay was carried out also on Δsdh6/pFl38 and Δsdh6/SDH6 as negative and positive 
control respectively.  
As indicated in the fig.8, the suppression exerted by YAP1 and YAP2 was not due to an 
increase of SDH activity. Therefore their suppression mechanism seemed to be 
independent of complex II and could be ascribed to an indirect effect of these two 
transcriptional factors. 
Moreover this result suggests that Sdh6p plays a dual role, one related to SDH functioning 
and the other independent from this. In this regard it may be significant and helpful to 
consider that mutants in SDH subunits with a similar residual SDH activity (~30/40%) are 
able to grow better than Δsdh6 mutant (fig.9) (Panizza Ph.D. thesis, 2011) suggesting 
that the inability to grow on non fermentable carbon sources of Δsdh6is not only due to a 
SDH defect. 
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Figure 3.9. Respiratory growth of several SDH2 mutants 
Therefore, these observations were indicative of an additional role of SDH6 besides the 
SDH assembly which had to be unraveled. Furthermore, the finding ofYAP1 and YAP2 as 
multicopy suppressors could be the key to elucidate this role. Thus, we focused on the 
cellular processes which are regulated by these two transcription factors and speculated 
that two main processes could be involved with Sdh6p: 
1. the oxidative stress response 
2. the mitochondrial iron metabolism 
Each hypothesis will be discussed individually. 
 
3.2.3. The oxidative stress response  
The oxidative stress response is a phenomenon by which a cell responds to alteration in 
its redox state due to the generation of radical oxygen species (ROS), potent oxidants 
capable of extensive cellular damage at the level of DNA, protein and membrane lipid 
content. ROS are caused by the incomplete reduction of O2 during aerobic respiration as 
well as to the exposure to ionizing radiations, redox cycling chemical present in the 
environment or to heavy metals (Jamieson, 1998; Rodrigues-Pousada et al., 2004). All the 
organisms, from bacteria to humans, have developed mechanisms to protect their cellular 
components against these reactive agents. Focusing on S. cerevisiae cells, there are both 
enzymatic and non-enzymatic defense systems to protect the cellular components and to 
maintain a balanced cellular redox state (Jamieson, 1998). Within the enzymatic system, 
one group is represented by superoxide dismutase (SOD) and catalase which act directly 
as ROS detoxifiers removing oxygen radicals and their products and/or repairing the 
damage caused by oxidative stress. The other group consists of enzymes which act as 
redox regulators of protein thiols and contribute to maintain the redox balance of the cell 
such as peroxidases which reduce inorganic and organic peroxides into the corresponding 
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alcohols using active site cysteine thiols (Herrero et al., 2008). These two groups overlap 
in the cell. Besides the enzymatic protection against ROS the non-enzymatic defense 
systems typically consist of small molecules which are soluble in either an aqueous or, in 
some instances, a lipid environment such as glutathione (GSH), ascorbate or vitamin E 
(Herrero et al., 2008). One of the mechanisms by which S.cerevisiae responds to the 
oxidative stress is altering its own transcriptional program (Ikner and Shiozaki, 2005) and 
Yap1, together with Skn7, is one of the transcription factors mainly involved in this kind of 
response (also Msn2/Msn4 are implicated in this specific stress response). In addition it is 
known that several mutants characterized by an increased sensitivity to the oxidative 
stress are unable to grow on respiratory carbon sources maybe because of the high ROS 
levels accumulated in the cell during respiration (Thorpe et al., 2004). Therefore 
considering that Yap1p is the major oxidative stress regulator we wondered whether 
Δsdh6 mutant could be more sensitive than a wt strain to the oxidative stress. In 
particular as exogenous oxidative stress were used H2O2 and menadione, a specific 
mitochondrial stress inducer that produces superoxide radicals by redox cycling in the cell 
damaging mtDNA (Klöhn and Neumann, 1997). 
 
Δsdh6 mutant is not sensitive to H2O2 and menadione  
To evaluate the sensitivity of Δsdh6 mutant a filter-paper disk method was performed 
with two different concentrations of H2O2 and menadione. 10e7 cells of each strains were 
plated on YNB+DO- URA glu 0.6% as described in material and methods section. 10 µl of 
H2O2 (2% and 5%) and menadione (20mM and 40mM) were adsorbed on sterile 
Whatman disks (diameter 9mm) placed in the middle of the plate. After 48h of growth at 
28 °C the plates were photographed as shown in fig.10 and fig.11. The strains used were 
the Δsdh6 mutant and wt BY4742 in addition to Δsdh6/YAP1 and Δsdh6/YAP2 in order to 
evaluate whether these two genes could in multicopy confer more resistance to the 
oxidative stress. 
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Figure 3.10. Paper disk assay with two different H2O2 concentrations. 
H2O2 2mM  H2O2 5mM 
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Figure 3.11. Paper disk assay with two different H2O2 concentrations. 
As shown in the figures 10 and 11, no differences among the strains were observed with 
H2O2 or menadione treatments. These results suggested that the OXPHOS rescue by YAP1 
and YAP2 was not due to an increased sensitivity to the oxidative stress in Δsdh6 mutant. 
Furthermore these results indicated that the rescue was maybe due to the general action 
of all genes controlled by these transcription factors and not only to the action of a 
specific target since no genes were found in the multicopy suppressors research besides 
YAP1 and YAP2. Indeed we tried also to overexpress GLR1, a gene encoding for the 
glutathione oxidoreductase known to be a target of YAP1 and involved in the oxidative 
stress response and we did not observe a growth rescue (data not shown) underlining 
once more that: 
- the single target of YAP1 was not sufficient to compensate the OXPHOS defect of 
Δsdh6 mutant; 
- the rescue dependent on YAP1 and YAP2 was due to the action of other genes not 
involved in the oxidative stress response. 
Therefore we focused on the second hypothesis we mentioned previously. 
 
Menadione 20mM  Menadione 40mM 
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3.2.4. The mitochondrial iron homeostasis 
Among several mechanisms in which YAP1 and YAP2 are involved, one is regulation of the 
iron metabolism. Indeed as previously described, the overexpression of these two genes 
confers resistance to the iron/zinc chelators 1, 10 phenantroline (Bossier et al., 1993; 
Schnell and Entian 1991). Moreover, the addition of iron (but not zinc or copper) 
alleviates the growth inhibition of Δyap1 mutant in alkaline medium (Schnell and Entian, 
1991). Furthermore we performed an analysis with the online tool YEASTRACT (Yeast 
Search for Transcriptional Regulators And Consensus Tracking), a database of more than 
48333 regulatory associations between transcription factors (TF) and target genes in S. 
cerevisiae based on bibliographic references (http://www.yeastract.com/). Noteworthy we 
found that several genes involved in the iron metabolism (not only mitochondrial) are 
controlled directly or indirectly by these two transcription factors. The following tables 
summarize the genes identified: 
 
- Iron transporters controlled by YAP1 
 
 
 
 
 
 
FRE1 Ferric reductase and cupric reductase, reduces siderophore-bound iron and oxidized copper 
prior to uptake by transporters; expression induced by low copper and iron levels. 
CCC1 Putative vacuolar Fe2+ transporter; suppresses respiratory deficit of yfh1 mutants, which 
lack the ortholog of mammalian frataxin, by preventing mitochondrial iron accumulation 
FRE6 Putative ferric reductase with similarity to Fre2p; expression induced by low iron levels 
FRE2 Ferric reductase and cupric reductase, reduces siderophore-bound iron and oxidized copper 
prior to uptake by transporters; expression induced by low iron levels but not by low copper 
levels 
FIT1 Mannoprotein that is incorporated into the cell wall via a glycosylphosphatidylinositol (GPI) 
anchor, involved in the retention of siderophore-iron in the cell wall 
FRE7 Putative ferric reductase with similarity to Fre2p; expression induced by low copper levels 
FRE4 
 
Ferric reductase, reduces a specific subset of siderophore-bound iron prior to uptake by 
transporters; expression induced by low iron 
MRS4 Iron transporter that mediates Fe2 transport across the inner mitochondrial membrane; 
mitochondrial carrier family member, similar to and functionally redundant with Mrs3p; 
active under low-iron conditions; may transport other cations 
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- Iron transporters controlled by YAP2 and shared with YAP1 
 
FRE1 
 
Ferric reductase and cupric reductase, reduces siderophore-bound iron and oxidized copper 
prior to uptake by transporters; expression induced by low copper and iron levels 
MRS4 
 
Iron transporter that mediates Fe2 transport across the inner mitochondrial membrane; 
mitochondrial carrier family member, similar to and functionally redundant with Mrs3p; 
active under low-iron conditions; may transport other cations 
 
On the basis of these findings we investigated whether the suppression exerted by YAP1 
and YAP2 was mediated by their role in iron metabolism. To answer to this question we 
evaluated whether the addition of iron to the medium could rescue the negative 
phenotype of sdh6 mutant likely miming the actions carried out by YAP1 and YAP2. 
 
The addition of iron to medium rescues the OXPHOS growth defect of  Δsdh6 
mutant 
It has been reported that Δyap1 mutant cannot grow in alkaline medium but the addition 
of iron to this medium is able to restore the growth of the mutant (Schnell and Entian, 
1991). To see if iron could have a similar effect also on the sdh6 mutant a serial dilutions 
growth test was performed adding FeSO4 to the medium. The oxidative growth of Δsdh6 
mutant and the parental strain was analyzed in a medium supplemented with three 
concentrations of FeSO4: 0.3mM, 0.75mM and 5mM added to YNB+DO+ 2% glucose, 2% 
ethanol and 2% K-acetate based-plates.  
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Figure 3.12. Spot assay in presence of different FeSO4 concentrations. 
We observed that the addition of iron was able to rescue the Δsdh6OXPHOS phenotype. 
The growth was particularly evident after 1 week of growth at 28°C and on ethanol as 
carbon source. This result led us to evaluate this rescue also on the mutant strains 
carrying YAP1 and YAP2. In this experiment, another iron concentration was added (7 
mM) as well as another carbon source (2% glycerol).  
 
BY4742
∆sdh6
2% GLUCOSE 
CONTROL       FeSO4 0.3mM FeSO4 0.75mM FeSO4 5mM
2% ETHANOL 
CONTROL      FeSO4 0.3mM FeSO4 0.75mM FeSO4 5mM
2% ACETATE 
CONTROL      FeSO4 0.3mM FeSO4 0.75mM FeSO4 5mM
BY4742
∆sdh6
BY4742
∆sdh6
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Figure 3.13. Spot assay in presence of different FeSO4 concentrations on the transformants strain carrying 
YAP1 and YAP2. 
The results of the spot-assay analysis showed that the rescue was possible both on 
ethanol and glycerol (fig. 13). Moreover these results led to two additional observations: 
1. the rescue on glycerol medium was possible only at 7 mM concentration; 
2. the addition of iron ameliorated the growth dependent by YAP1 and YAP2 
compared to the control without iron. 
In order to exclude that the observed growth was due to the presence of sulfur in the 
medium, the same experiments were made with FeCl2 and the spot assay is reported in 
fig.14. 
2% GLUCOSE 
CONTROL         FeSO4 0.3mM FeSO4 0.75mM   FeSO4 5mM    FeSO4 7mM
2% ETHANOL 
CONTROL         FeSO4 0.3mM FeSO4 0.75mM   FeSO4 5mM    FeSO4 7mM
2% GLYCEROL
CONTROL         FeSO4 0.3mM FeSO4 0.75mM   FeSO4 5mM    FeSO4 7mM
2% ACETATE
CONTROL         FeSO4 0.3mM FeSO4 0.75mM   FeSO4 5mM    FeSO4 7mM
∆sdh6/SDH6
∆sdh6/pFL38
∆sdh6/YAP1
∆sdh6/YAP2
∆sdh6/SDH6
∆sdh6/pFL38
∆sdh6/YAP1
∆sdh6/YAP2
∆sdh6/SDH6
∆sdh6/pFL38
∆sdh6/YAP1
∆sdh6/YAP2
∆sdh6/SDH6
∆sdh6/pFL38
∆sdh6/YAP1
∆sdh6/YAP2
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Figure 3.24. Spot assay in presence of different FeCl2 concentrations on the transformants strain carrying 
YAP1 and YAP2. 
Again, we observed a rescue of OXPHOS defect either in ethanol and glycerol medium 
underlining that the rescue was dependent on the iron element. Furthermore, the strains 
transformed with YAP1 and YAP2 grew better than the control in presence of iron. In 
addition the effect of iron on the oxidative growth was specific for Δsdh6 mutant since no 
amelioration of growth was observed for other sdh mutants (sdh1-5, data not shown) in 
presence of iron salts. The reason why the “iron rescue” is observed only in ethanol and 
glycerol and not in acetate medium is not clear. One reason could be the toxicity of K-
acetate in S.cerevisiae cells. In particular, the K-acetate can be toxic for the cells and 
actually it is known that Δsdh6 mutant is not able to grow when ethanol and acetate are 
both present in the medium (although in ethanol it should grow poorly). Another possible 
reason for the absence of growth could be due to the iron chelating action of organic 
acids such as TCA intermediates: in this mutant this action could be exerted by succinate 
2% GLUCOSE  
CONTROL               FeCl2 0.3mM FeCl2 0.75mM 
2% ETHANOL 
CONTROL               FeCl2 0.3mM FeCl2 0.75mM 
∆sdh6/SDH6
∆sdh6/pFL38
∆sdh6/YAP1
∆sdh6/YAP2
2% GLYCEROL
CONTROL               FeCl2 0.3mM FeCl2 0.75mM 
2% ACETATE 
CONTROL               FeCl2 0.3mM FeCl2 0.75mM 
∆sdh6/SDH6
∆sdh6/pFL38
∆sdh6/YAP1
∆sdh6/YAP2
∆sdh6/SDH6
∆sdh6/pFL38
∆sdh6/YAP1
∆sdh6/YAP2
∆sdh6/SDH6
∆sdh6/pFL38
∆sdh6/YAP1
∆sdh6/YAP2
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which is accumulated as a consequence of specific SDH impairment (Szeto et al., 2007). 
Interesting was the work of Lemire group in which they analyzed the metabolomics of 
SDH mutants. They observed that the impairment of SDH activity was accompanied by 
large amounts of extracellular acetate: this result can lead to speculate that whatever is 
the effect of acetate on our mutant, this effect could be strengthened by the extracellular 
acetate secretion (Szeto, 2010). 
 
The addition of iron does not increase the SDH activity in Δsdh6 mutant 
These data led us to consider whether the addition of iron could partially restore SDH 
activity. We evaluated SDH in Δsdh6 and BY4742 grown both in glucose 0.6% and 
ethanol 2% plus FeSO4. The iron concentration chosen was 0.75mM and was added 
directly to the ethanol medium.  
 
Figure3.35. SDH assay in presence of FeSO4 in the medium. 
As expected no increase of SDH activity was observed with the addition of iron salts to 
the medium. Therefore, as previously observed for the Δsdh6 mutant overexpressing 
YAP1 and YAP2 also the rescue exerted by iron was not mediated by an increase of SDH 
activity. 
The results so far obtained once more favor the hypothesis that Sdh6p has a second role 
in the cell besides the SDH assembly. It is possible to speculate that the OXPHOS 
negative phenotype of Δsdh6 mutant is both due to a reduced SDH activity and to a lack 
of another putative cellular function. We hypothesized that this second role may be linked 
to iron metabolism/homeostasis since both overexpression of YAP1 and YAP2 and the iron 
supplementation are able to restore the oxidative growth without increasing SDH activity.  
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The observation that a residual enzymatic activity of about 30-40% is sufficient to 
partially support an oxidative growth (see fig 3.9) favors this hypothesis.  
However the mechanism (direct or indirect) by which YAP1 and YAP2 can regulate iron 
mobilization/availability in the Δsdh6 mutant remains to be elucidated. 
Examples of growth without an amelioration of complex II activity are known in literature. 
A recently work of Gonzales et al., showed that the Δyfh1 strain characterized by an 
abnormal growth in respiratory conditions, was rescued by addition of FAD 10 µM to 
medium (Gonzalez-Cabo et al., 2010). Strikingly, all the respiratory complexes activities 
which were significantly impaired in the mutant, were increased by FAD except complex 
II. Thus the authors suggested that FAD effect on growth improvement of frataxin-
deficient cells was independent of complex II. Furthermore, they speculated that the 
growth capability on a respiratory medium without an intact respiratory chain able to 
guarantee the transport of electrons to CoQ, was due to the electron transfer flavoprotein 
(ETF) complex. In mammalian this system is composed by the ETF-dehydrogenase (ETF-
QO) and ETF, a heterodimer made of two subunits (ETFa and ETFb), that delivers 
electrons coming from β-oxidation of fatty acids and amino acid catabolism to CoQ 
(Eaton, 2002). In S. cerevisiae there is a putative gene YPR004C as the ETFa homologue 
and YGR207C as the homologue of ETFb. The authors therefore speculated that the 
observed growth was due to the FAD action on complex I and ETF complex (Gonzalez-
Cabo et al., 2010). Although this example showed as a growth was possible without a 
rescue of enzymatic activity, the underlain explanation is not suitable for the Δsdh6 
mutant (FAD did not rescue the negative Δsdh6 phenotype, data not shown). Indeed this 
putative ETF-complex should already support the growth of this mutant in physiological 
conditions. As previously suggested the observed rescue could be a consequence of the 
suppression exercised on a defect associated to the additional role of Sdh6p on which 
both YAP genes and iron act. 
 
BPS treatment is detrimental for Δsdh6 mutant 
Since the addition of iron caused an amelioration of Δsdh6 growth, we wondered what 
could happen in a condition of deprivation of iron. Therefore we used the Fe(II) chelator 
bathophenantholine disulfonic acid (BPS), 40 µM and 80 µM, to prepare glucose and 
ethanol plates. 10e5 cells of Δsdh6 and BY4742 were spotted for each condition indicated 
in fig 16 with or without BPS. 
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Figure 3.16. Treatments with two different BPS concentrations 
As depicted in fig. a marked decrease of Δsdh6 growth on ethanol was visible in presence 
of BPS. In particular if we compare the spots on 40 µM BPS it is evident how the sdh6 
mutant is more sensitive than wt despite the same amount of cells were spotted as 
indicated in the control spot. Conversely, on glucose medium no differences between  
Δsdh6 and BY4742 were visible. Therefore it is possible to speculate that the absence of 
iron is deleterious for the viability of Δsdh6 mutant in respiratory medium. We evaluated 
the growth only in ethanol as carbon source since here it is possible to appreciate a 
growth of this mutant. 
Considering that the iron supplementation was positive for the growth on respiratory 
carbon sources of sdh6 mutant and that on the contrary, its absence was detrimental, we 
investigated whether and how the SDH6 expression was modulated by addition or 
depletion of iron. 
 
SDH6 expression is induced by iron 
In order to evaluate the expression of SDH6 in presence or absence of iron, total RNA 
from BY4742 grown in several conditions were extracted. In particular BY4742 was grown 
in: 
 2%Glucose  
 2%Glucose + Fe 0.75 mM 
 2%Ethanol  
 2% Ethanol + Fe 0.75 Mm 
 2%Glucose + BPS 
As described in the material and methods section, a Retro-Transcription reaction was 
carried out to obtain cDNAs to be processed with a standard PCR. The PCR products were 
run in a 2% agarose gel and the results are represented in the following figure.  
BY4742
sdh6∆
-
2% GLUCOSE               2% ETHANOL
-
BY4742 
 
 
Δsdh6 
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Figure 3.17. Expression of SDH6 in presence or absence of iron. Transcripts of SHD6 were detected by RT-
PCR of total RNA from BY4742 grown in YP added with the different carbon sources. RT-PCR control for all 
samples is represented by the amplification of TAF10. The cells were stocked at 1 OD.  
The expression pattern shown in the fig 17 indicated that SDH6 is induced by iron. 
Indeed, in a medium containing glucose plus iron we can observe an increased SDH6 
signal while TAF10 remains constant. In ethanol we cannot appreciate the induction by 
iron since, as described in the chapter II, ethanol itself determines a SDH6 upregulation. 
Furthermore, we evaluated the expression of SDH6 in a medium with BPS. A marked 
decrease of SDH6 signal was observed despite the loading control assured the presence 
of RNA. This result supports the hypothesis that Sdh6p can be involved in the metabolism 
of iron and not in its transport within the cell because in this case in absence of iron its 
upregulation should be expected. These speculations require further investigations. 
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CONCLUDING REMARKS 
Despite the great knowledge on the function and structure of the SDH complex, little is 
known about its assembly intermediates, factors involved, the timing as well as the 
mechanism of the addition of the various prosthetic groups. Only in the 2009 two 
assembly factors specific for SDH complex have been identified: SDH6/YDR379C-A and 
SDH5 in yeast, in human SDHAF1 and SDHAF2 respectively.  
While it is clear that Sdh5p is involved in flavination of Sdh1p subunit, nothing is known 
about the action mechanism of Sdh6p.  
The work presented in this thesis has given more insights into the knowledge of SDH6 
through genetic and biochemical studies performed in the yeast S. cerevisiae. 
In particular the results described in the first part were focused on understanding the role 
of Sdh6p in the assembly and full functioning of SDH complex. Through 2D-BNGE analysis 
a marked reduction of complex II was observed in Δsdh6. This result definitely 
demonstrated that defective SDH activity is caused by a reduced number of enzyme units 
rather than by qualitative alterations of complex II. Furthermore both the fact that Sdh6p 
is required for a full assembly of complex II and that it is a rate limiting step in this 
process are supported by experimental evidence. The decrease of SDH activity indeed 
cannot be bypassed over-expressing the four SDH subunits in the mutant. Moreover the 
steady state levels of SDH subunits 1 and 2 are decreased in Δsdh6 as pointed out in  
SDS-PAGE analysis. An interesting contribute was given by the biochemical analyses 
performed with the recombinant variants of Sdh6 tagged protein. Indeed the results 
obtained performing a 2D-BNGE analysis on the strain expressing Sdh6p-HA indicated that 
Sdh6p does not establish stable physical contact with complex II nor it takes part to other 
molecular complexes. In addition affinity purification analyses demonstrated that Sdh6p is 
not an interactor of subunit 1 and 2 of SDH complex, since these two proteins are not 
eluted together with Sdh6p. 
The results obtained in this work suggested that SDH6 plays a different role from that 
played by SDH5, the other conserved SDH assembly factor. Indeed neither the 
overexpression of SDH6 rescues the OXPHOS defect of Δsdh5 and nor the expression in 
multicopy of SDH5 is able to restore the respiratory growth of sdh6 mutant. Therefore the 
two SDH specific assembly factors are not interchangeable.  
To evaluate whether Sdh6p was necessary for the insertion or assembly of Fe-S clusters 
into complex II we performed a genetic interaction study between SDH6 and ISD11. 
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ISD11 encodes for an essential protein of the ISC biogenesis and as well as SDH6 
contains a LYR motif that is a signature for proteins involved in Fe-S metabolism. 
Moreover the two proteins show a significant similarity. As already discussed, SDH 
complex contains three Fe-S centers but nothing is known about the mechanism of 
insertion of these clusters in the backbone of CII. The overexpression of ISD11 did not 
rescue the SDH defect due to the sdh6 mutation. The experiments performed so far, 
albeit not exhaustive, do not favor an involvement of Sdh6p in Fe-S centers biogenesis. 
 
To further investigate the functional role of SDH6 a search for multicopy suppressors was 
performed. This analysis identified YAP1 and YAP2, two transcription factors involved in 
several cellular processes. Although YAP1 and YAP2 are able to rescue the OXPHOS defect 
of sdh6 mutant, their action is not exerted by increasing the SDH activity. Therefore their 
suppression mechanism seems to be independent of complex II and could be ascribed to 
an indirect effect of these two transcriptional factors.YAP1 and YAP2 might suppress the 
OXPHOS negative phenotype by compensating some other cellular defects which are 
impaired in the sdh6 mutant.  
Thus Sdh6p should have an additional role besides the SDH assembly: in this case the 
OXPHOS negative phenotype of the null sdh6 mutant would be due to both a reduced 
SDH activity and to a lack of the other putative function. The observation that several sdh 
mutant with a 30-40% of residual SDH activity are able to grow on oxidative carbon 
sources much better than sdh6 mutant strengthens this hypothesis. 
In order to understand the mechanism of suppression exerted by YAP1 and YAP2 we 
focused on two main functions linked to these genes: the oxidative stress and the iron 
metabolism. The first was chosen since Yap1p is a master oxidative stress gene regulator 
in the yeast cells. The second because among targets of Yap1p and Yap2p there are 
genes encoding for iron transporters. In addition it is worth mentioning that YAP1 and 
YAP2 were identified in a multicopy suppressors research since they were able to confer 
resistance to the iron chelators 1,10-phenantroline and 1-nitroso-2-naphtol. On the basis 
of the results obtained we favor the hypothesis that the suppression mechanism exercised 
by YAP1 and YAP2 could be mainly ascribed to their role in iron metabolism/homeostasis. 
Moreover when the effect of iron supplementation on the oxidative growth of the Δsdh6 
strain was tested a rescue of the OXPHOS phenotype was observed without any increase 
of SDH activity. The results obtained support the view that the second role of Sdh6p could 
be related to iron metabolism/homeostasis. Further analysis will be necessary to unravel 
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this hypothesis and the measurement of the iron intracellular content could be for 
instance a useful tool to investigate in the sdh6 mutant a possible imbalance of the iron 
homeostasis. 
In order to dissect the two possible functions of SDH6, the one linked to cII assembly 
from that related to the iron metabolism response and in order to identify which amino 
acid residues within Sdh6p are critical for its function in vivo two approaches will be 
pursued. First, a search for multicopy suppressors of the strains carrying the two 
pathological mutations will be carried out. To this purpose the pathological alleles 
SDH6R55P and SDH6G57R have been integrated at SDH6 locus and the two mutants strains 
have been constructed. This analysis could provide different information respect to that 
obtained with the search for multicopy suppressors previously performed. Indeed, the 
suppression of the null mutation generally creates a bypass, whereas the suppression of 
missense mutations may identify interactors. Second a collection of random sdh6 point 
mutants will be generated and analyzed. The intragenic and extragenic suppressors 
identified being able to restore the respiratory competence of the negative mutant will be 
then selected and characterized. 
All together these analyses will allow to identify putative SDH6 interactors which might 
clarify the role of this gene within the cell. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and Methods 
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Miscellanea 
 
Strains used 
- S.cerevisiae strains 
NAME GENOTYPE REF 
BY4741 Mat a, his3∆1, leu2∆0, met15∆0, ura3∆0 
(Brachmann 
et al., 1998) 
 Δsdh6 BY4741 ydr379c-a::KANMX4 (Brachmann 
et al., 1998) 
Δsdh5 
BY4741 yol071w::KANMX4 (Brachmann 
et al., 1998) 
Δtcm62  
BY4741 ybr044c::KANMX4 (Brachmann 
et al., 1998) 
BY4742 MATα his3Δ1 leu2Δ0 lys2Δ0 ura3Δ0 (Brachmann 
et al., 1998) 
 Δsdh6 BY4742 ydr379c-a::KANMX4 2009, our 
laboratory 
W303-1a MATa leu2-3112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15 (Brachmann 
et al., 1998) 
W303-1b MATα leu2-3112 trp1-1 can1-100 ura3-1 ade2-1 his3-11,15 (Brachmann 
et al., 1998) 
 Δsdh6 W303-1a ydr379c-a::KANMX4 
W303-1b ydr379c-a::KANMX4 
This study 
isd11BY4743 Mat a/α, his3Δ1/ his3Δ1; leu2Δ0/ leu2Δ0; lys2Δ0/LYS2; 
MET15/met15Δ0; ura3Δ0/ura3Δ0; 
YER048w-a::kanMX4/YER048w-a 
(Brachmannet 
al., 1998) 
nfs1 BY4743 Mat a/α, his3Δ1/ his3Δ1; leu2Δ0/ leu2Δ0; lys2Δ0/LYS2; 
MET15/met15Δ0; ura3Δ0/ura3Δ0; 
YCL017c::kanMX4/YCL017c 
(Brachmann 
et al., 1998) 
jac1 BY4743 Mat a/α, his3Δ1/ his3Δ1; leu2Δ0/ leu2Δ0; lys2Δ0/LYS2; 
MET15/met15Δ0; ura3Δ0/ura3Δ0; 
YGL018c::kanMX4/YGL018c 
(Brachmann 
et al., 1998) 
yah1 BY4743 Mat a/α, his3Δ1/ his3Δ1; leu2Δ0/ leu2Δ0; lys2Δ0/LYS2; 
MET15/met15Δ0; ura3Δ0/ura3Δ0; 
YPL252c::kanMX4/YPL252c 
(Brachmann 
et al., 1998) 
 
- Bacterial strains 
NAME GENOTYPE REF 
DH10B Mat a, his3∆1, leu2∆0, met15∆0, ura3∆0 
(Brachmann 
et al., 1998) 
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Media and growth conditions 
For yeast the following media were used:  
 YP (1% peptone, 0.5% yeast extract),  
 YPA (2% peptone, 1% yeast extract, 7.5mg/ml adenine),  
 YNB (YNB ForMedium™ w/o aminoacids w/o NH4SO4 1,9 g/L, NH4SO4 5 g/L). 
Minimum media was enriched with drop-out powder (Kaiser et al., 1994) . If 
necessary singles aminoacids could be excluded from complete drop-out to 
maintain selective pressure .  
 5-FOA YNB: YNB ForMedium™ with 1 g/l 5-Fluoroorotic Acid (Melford), 50 mg/l 
uracile with aminoacids necessary to complement the auxotrophies (Boeke et al., 
1984). 
 Sporification Medium: 2% potassium acetate, 0.25% yeast extract ForMedium™. 
As solidifying agent 2% agar ForMedium™ was added. 
Carbon sources were added at final concentration of 2% if not specified differently. The 
following sources were used: Glucose (D), Ethanol (E), Glycerol (G), Potassium Acetate 
(A).  
S. cerevisiae was cultured at 28˚C, in constant shacking 120 rpm if liquid media was 
used.  
 
For E. coli LB media was used (1% bacto tryptone Difco™, 0.5% yeast extract Difco™, 
0.5% NaCl, pH 7.2-7.5). Agar 2% and ampicillin (Sigma-Aldrich®) 100mg/ml were added 
if needed. For α-complementation selection 80µl of 5-bromo-4-chloro-3-indolyl-b-D-
galactopyranoside (Xgal) 2% (dissolved in dimethilformamide) and 40µl isopropyl-beta-D-
thiogalactopyranoside (IPTG) 23,8 mg/ml were added.  
E.coli cultures were incubated at 37˚C in constant shacking if necessary. 
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Plasmids  
In particular for this study the following plasmids were used: 
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Polymerase Chain Reaction 
All the reactions were performed following manufacturer indications. For analytical 
purpose Taq DNA polymerase 2X master mix (NEB) or GoTaq® DNA polymerase 
(©Promega) were used. Preparative reactions for gene cloning were performed with a 
high fidelity polymerase. KOD HiFi DNA polymerase was used (Novagen®). 
For the yeast colony PCR cells were suspended in 10 µl H20 after 24h of growth in 
selectable medium. 3 µl were utilized for the PCR reaction and after 15’ at 95 °C the 
standard PCR reaction was carried out adding GoTaq® DNA polymerase (©Promega). 
The primers utilized are the following: 
- Cloning primers 
 
- Tag primers 
 
 
 
 
 
 
 
- Control primers (for colony PCR) 
 
 
 
 
 
Target gene Oligo sequence Restriction site at 5’ end 
ISD11 
 
Fw: GGATCCATGTCCACAGTAAAGTAGAT 
Rv: AAGCTTCTTATAGTCCCATGTGG 
BamHI 
HindIII 
GLR1 
 
Fw: CCCCGAATTC CAGCATTGAAAGCGTGGAAG 
Rv: CCCCAAGCTT GAGTCCACAGTAGCTAATAG 
EcoRI 
HindIII 
SDH5 Fw: CCCCGGATCCCGCGCAAACTGTTTCCCACAG 
Rv: CCCCAAGCTTGATGGTGCAACAACAATAATA 
BamHI 
HindIII 
SDH6 Fv:  GAATTCCGGTAAATGACGGCTATCCGCG 
Rv: CTGCAGGCAAGCATAATACAGATTTGC  
BamHi 
PstI 
TCM62 Fw: CCCCGAATTCCCGCTATCTGTGGGAGTGA 
Rv: CCCCCTGCAGAGGATACAAGGACACAG 
EcoRI 
PstI 
YAP1 Fw: CCCCGAATTCGCTGATCTTACCCTGTTGCA 
Rv: CCCCAAGCTTCCGAGGTGATACAATCTACCT 
EcoRI 
HindIII 
YAP2 Fw: CCCCGGATCCGCTCTGGACAAGTACCAGTT 
Rv: CCCCCTGCAGAGGTATCCACTTGTATCGGA 
BamHI 
PstI 
YFH1 
 
Fw:GGGGGGATCCCCGTATAGATTCATGCTCCGGAC 
Rv:CCCCCTGCAGCTTCAGTGCAGGTATTGCGTGG 
BamHI 
PstI 
Target gene Oligo sequence 
SDH6-HA 
 
Rv:CTGCAGAAGTAAGAAAATAGTTCAAGCGTAATCTGGAA 
CATCGTATGGGTAATGTATATTCGTCAGTTCAGGGTGTGA 
SDH6-HIS Rv:GGGGCTGCAGAGTAAGAAAATAGTTCAGTGGTGGTGGT 
GGTGGTGATGTATATTCGTCAGTTCAGGGTGTG 
Target gene Oligo sequence 
SDH6 
 
Fw:GTCTTACACCTGTATAGGGC 
Rv: CGTCATTCAGGGTGTGAAAAG 
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E. coli transformation 
E. coli transformation was achieved with electroporation. Competent cells were prepared 
as previously described (Dower et al., 1988). Transformation was carried out with 1-3µl of 
plasmid DNA or ligation product. One mm or 2 mm cuvettes were used, applying 
respectively a current of 2KV, 25 F 200 . 
Alternatively, CaCl2 competent cells were prepared and transformed with standard 
techniques (Maniatis et al., 1982). 
 
S. cerevisiae transformation 
Yeast transformation was carried out with Lithium Acetate (LiAc) as described by Gietz et 
al. If a greater efficiency was desired, the long protocol was applied (Gietz et al., 2002). 
For the one step gene disruption the cells were regenerated in two ml of YPAD for 2 h 
and then plated on plates added with G418. 
 
Integration of mutant alleles R55P and G57R at SDH6 locus 
The integration at SDH6 locus requires two principal genetic steps: 
- the substitution of KanMX cassette with URA3 cassette in Δsdh6 mutant (Fig.2.A) 
(Voth et al., 2003). 
- the subsequent substitution of URA3 cassette with the R55P and G57 alleles 
(Fig.2.B) 
This strategy was possible thanks to the plasmid M4758 (fig.1) which contained the URA3 
cassette flanked both ends by parts of KanMX cassette.  
 
Figure4.1. M4758 plasmid  
A scheme of this genetic approach is reported below: 
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A.                                    B.                            
   
Figure 4.2. Scheme of mutant alleles integration at SDH6 locus. (A.) The first step substitutes KanMX 
cassette with URA3. (B). Integration of SDH6R55P and SDH6G57R cassette. 
M4758 plasmid was digested with NotI and two fragments were obtained: one of 1700 bp 
containing URA3 cassette and the other of 2400 bp with the rest of plasmid. Following the 
digestion, Δsdh6 (Δsdh6::KanMX) was transformed with the long protocol described by 
Woods and Gietz. The selection of transformants was carried out on selectable medium 
without uracile. Transformants were also controlled on G418 containing plates. The 
transformants able to grow both on uracile and G418 based-medium in which the 
homologous recombination was correctly occurred, were transformed with the whole 
SDH6R55P and SDH6G57R cassettes obtained by PCR. The protocol was the same used 
before. The cells were plated on YPD and replicated on 5-FOA containing plates after 24h 
at 28°C. A PCR on genomic DNA extracted was performed to assure the correct cassette 
integration. 
Subsequently, spot assays were carried out to evaluate the transformants phenotypes.  
 
Multicopy suppressors research 
The sdh6::KanMX strain was transformed with the standard LiAc method (Gietz et al., 
2002) and the pSEY8 (URA3) genomic library was used (300ng). Transformants were 
plated on YNB+ DO- URA added with 2%glucose. After growth at 28 °C the cells were 
replicated on YNBAcetate plates and the growth of suppressor clones was observed. All 
the clones were subsequently analyzed by PCR to exclude the clones able to grow thanks 
to the wt gene. Then the plasmids were recovered from the Ace+ transformants and were 
sequenced at both ends with universal primers. The genes were identified through a 
BLAST research. A plasmid loss was carried out to correlate the growth on YNBA to the 
plasmids contained in the cells. 
 
 
KanMX BY4742/Δsdh6
URA3 M4758  NotI digestion
URA3 Δsdh6::URA3
R55P
G57R
R55P EcoRI/HindIII
G57R EcoRI/HindIII
URA3 Δsdh6::URA3
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Plasmid loss 
Each clone Ace+ was inoculated in 10 ml of YPD 2% in order to induce the loss of 
plasmids. After 24h of growth, 200 cells were plated on YPD plates and then were 
replicated on YNBA - uracile. So the growth on acetate based medium was linked to the 
presence of the plasmids in the cells. 
 
Nucleic Acids manipulation 
All the manipulations were carried out with standard techniques (Maniatis et al., 1982).  
 Plasmid DNA was extracted from E. coli with Wizard® Plus SV Minipreps, Wizard® 
Plus Minipreps (©Promega) or following standard procedures (Maniatis et al., 
1982). DNA recovery from agarose gel and purification of PCR products were 
carried out with Wizard® SV Gel and PCR Clean-up System (©Promega) 
commercial kit. 
 Genomic DNA from S. cerevisiae was extracted as previously described (Hoffman 
et al., 1987; Looke et al., 2011).  
 Enzymatic manipulations (restriction, ligation, dephosphorylation) were carried out 
following manufacturer indications (New England Biolabs® Inc. NEB, Invitrogen™). 
 Sequencing was performed with external services (©Eurofins-MWG). 
 RNA extraction was perfomed as described by Ausubel et al. (Ausubel et al., 1994) 
and quantified. 
RT-PCR 
Probes 
Target gene Oligo sequence 
SDH6 
 
Fw:GTCTTACACCTGTATAGGGC 
Rv: CGTCATTCAGGGTGTGAAAAG 
TAF10 
 
Fw:ATATTCCAGGATCAGGTCTTCCGTAG 
Rv: GTAGTCTTCTCATTCTGTTGATGTTGT 
 
Reaction I: 
Material needed:    3 µg total RNA 
     3 µl DNAse I Buffer (Invitrogen™) 
     3 µl DNAse I (Amp Grade Invitrogen™) 
    H20+DEPC 1% (diethyl pyrocarbonate treated)  
to a final volume of 30 µl 
 
99 
 
Protocol: 
For each sample, 3 µg RNA were utilized.  
1. Add 3 µl DNAseI (Invitrogen™) and incubate the samples 15’ at room T. 
2. Add 3 µl EDTA 25 mM to inactivate DNAse I and incubate the samples 10’ at 65 
°C. 
3. Precipitate the reactions with 1/10 vol NaAc 3M pH 5.2 and 2.5 vol of ETOH96%. 
Freezing with N2 before storing at -80 °C overnight. 
 
Reaction II: 
Solutions needed:    H20+DEPC 1%  
     Oligo dT [Oligo(dT)15 Primer] 
     RT BUFFER 10X (NEB Biolabs) 
     5mM dNTPs 
     RNAse-OUT (Invitrogen™) 
     M-MuLV Reverse transcriptase  (NEB Biolabs) 
 
Protocol: 
1. After precipitation, resuspend RNA pellets in 16 µl H20+DEPC 1% and the samples 
are split in two eppendorf tubes: one will be for the control without Reverse 
Transcriptase. 
2. Add 1 µl oligo-dT and incubate the samples 10’ at 70°C.  
3. In ice, add the following components in a final volume of 20 µl:  
     RT-BUFFER (10X)        2     µl 
dNTP (2,5 mM)           4     µl                
Rnasi-OUT                 0,5   µl                       
Reverse Transcriptase 1     µl 
H2O + DEPC 1%        3,5   µl 
Transcriptase is added to all samples except for the control 
4. Incubate the samples at 42°C for 2h and stop reactions with heat inactivation 
(70°C for 15’ ) 
5. Process the samples with PCR or stock them at -20°C. 
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PCR Reaction 
cDNAs are diluted 1:10 and 2 µl are utilized for a normal PCR reaction with GoTaq® DNA 
polymerase (©Promega). The PCR reactions were performed following manufacturer 
indications. PCR products were run on a 2% agarose gel and controlled. 
 
Protein separation with SDS-page  
Protein separation with SDS-page was performed with classical Laemmli system (Laemmli,  
1970). Separating gels were prepared at 12% or 15% polyacrylamide (36:1 acrylamide-
bis), stacking gel at 5%. Running was performed for 1hr 30’ at 100-120volts in a Mini 
Trans-Blot cell (BIORAD). 
 
Blue Native Gel Electrophoresis  (BNGE) 
Isolated mitochondria were treated as described by Nijtmans et al. (2002). 150 µg were 
solubilized with 1% Lauryl maltoside and the extracts were loaded and run into a 5-13% 
gradient non-denaturing 1D-BNGE. For denaturing 2D-BNGE, the 1D-BNGE lanes were 
excised and treated for 1h30’ at room temperature with 1% SDS, 1% β-mercaptoethanol 
and then run through a 16.5 % tricine-SDS-polyacrylamide gel using a 10% spacer gel 
(Schagger and von Jagow, 1987).  
 
Western Blotting and Ig-detection 
Separated proteins were transferred to nitrocellulose membrane (GE Healthcare) by 
electroblot for 1hr 15’ at 100V or overnight at 20V. The electroblotting system was used. 
Quality of the blot was assessed with Ponceau S staining. 
Membranes were blocked 1hr with 5% non-fat dry milk prepared in washing buffer (TBS 
1X+ Tween 0.1%) and incubated o/n with appropriate primary antibody (mono or 
polyclonal). 
Blocked membranes were washed 3 times for 15 min with washing buffer prior incubation 
with suitable secondary antibodies (Anti-Rabbit, Anti-Mouse and Anti-Rat) conjugated with 
horseradish peroxidase (1:5000 in 5% milk). 
The antibodies used in this study were: 
- Anti-Sdh2 against the subunit 2 of SDH complex (a kind gift from Dott. B.Lemire) 
- Anti-Atp4 against the subunit 4 of Complex V (a kind gift from Prof. J. Velours) 
- Anti-HA against the hemagglutinin epitope of Sdh6p-HA fusion protein (Roche 
Applied Science) 
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- Anti-His against the SDH6-HIS fusion protein (Bethyl Laboratories inc) 
 
After 1hr incubation membranes were washed as above and developed with ECL™ 
Western Blotting Detection Reagents (GE Healthcare) commercial kit. If greater sensitivity 
was necessary the ECL™ Advance Western Blotting Detection Reagents (GE Healthcare) 
kit was utilized. 
 
Whole cell analyses 
Spot Assay  
Spot assay is a classical phenotypic analysis used to test growth of single strains in 
different conditions. The principle is a 10-fold serial dilution of a starting culture at 1*10e7 
cells/ml, performed four/five times to a final 1*10e4 cells/ml or 1*10e3 cells/ml.  
After a o/n culture at 28 °C in YPD or YNBD the OD600 was measured for each strain. A 
first dilution was made to dilute each strain to a concentration of 1 OD (1*10e7). Then 
three or four 10-fold serial dilutions were made. From these suspensions 5µl or 10µl were 
spotted in ordered rows on agar plates and then incubated for several days. 
 
Filter paper disk-method 
This assay allows to evaluate the strain sensibility to specific substances. 20 ml of YNBD + 
DO - Ura + 2% Agar were plated and once solidified covered with a 10 ml of cells/Top 
agar in order to have a total concentration of 1*10e6 cells. These cells were pre 
inoculated in YNBD +DO - Ura and incubated o/n at 28 °C. After measuring OD600, cells 
were inoculated in 10 ml of Top agar. Once the second lay was solidified, a Whatman disk 
was placed in the plates centre. 10 µl of the testing substance were added on the disk 
and after an incubation at 28 °C for 3-4 days, the halos were observed. 
 
Cytochromes spectra absorption 
(Ferrero et al., 1981) 
Mitochondrial respiratory chain intactness can be assessed easily recording the 
cytochromes absorption profile on whole cells. All the experiments were carried out with a 
Cary 300Scan UV-vis spectrophotometer (Varian Inc.), recording continuously from 630 to 
540nm. The following general protocol was used: 
1. Pre inoculate the strains in 10ml YPD or YNBD+DO- Ura and incubate o/n at 28°C 
2. Inoculate 2.5ml in 100ml of YPD 0.6% or YNBD+DO-Ura and incubate 24hrs at 28°C 
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3. After checking that glucose is finished (to be sure that any repression is affecting the 
cells) harvest cells centrifuging 5000rpm 10 minutes, 4˚C 
4. Resuspend the cells in water proportionally to their humid wet (to normalize 
concentration among different strains) 
5. Register the spectra oxidized versus reduced. 
Raw data were processed using Excel functions (Microsoft® Office). WT strain was 
included in each analysis. 
 
Oxygen consumption 
(Ferrero et al., 1981) 
Oxygen consumption was recorded using Oxygraph system from Hansatech, composed of 
a S1 Clark electrode core controlled with Oxygraph Plus software (Hansatech Instruments 
Ltd.). Cells were obtained as described for cytochromes spectra recording. 100µl were 
added to 900µl of K-ftalate 0.1M pH5 in the chamber. Oxygen decrease was recorded for 
at least 1 minute. 100µl of cell suspension were exsiccated at 37˚C for 48hrs and dry wet 
estimated. Oxygen consumption rate was expressed as nmol O2 for minute for mg of cells 
(nmol/min mg). 
 
mtDNA stability Analysis 
mtDNA stability was evaluated by the frequency of spontaneous cytoplasmic petite. They 
grow as small colonies on medium supplemented with respiratory carbon sources such as 
ethanol and glycerol. The protocol is the following: 
1. The pre existing petite are counter-selected on YPE 2% medium 
2. Replicate the YPE 2% plates on selectable medium supplemented with 2% 
glucose. The strains are grown for 24h at 37°C. 
3. Replicate on a new plate of the same medium and incubate again for 24h. 
4. Resuspend a part of cells in H2O and evaluate the cellular concentration.  
5. Plate 250 cells on poor medium supplemented with 0.2% glucose and 2% ethanol. 
Incubate at 28°C for 3-4 days and count the cells. 
0.2% glucose is added in order to allow the growth of petite mutants which are 
respiratory deficient and are unable to use ethanol like the “wt” cells. Indeed the petite 
mutants will form small colonies unlike the big colonies formed by wt cells. For further 
controls, the single colonies can be patched on a medium containing a respiratory carbon 
source. 
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Mitochondrial Analysis 
Preparation of yeast mitochondria with intact outer membrane 
(Glick et al., 1995) 
1. Harvest cells at 2000-3500 rpm for 7 minutes and wash once with sorbitol 1.2M 
2. Resuspend washed cells in digestion buffer at concentration of 1gr of cells in 3ml 
Digestion Buffer:   30ml 2M sorbitol 
    3ml 1M phosphate buffer, pH 7.5 
    0.1ml 0.5M EDTA pH 8 
    0.5ml ß-mercaptoethanol 
    50mg of zymolyase 20000 
    16ml of water (Vf=50ml) 
Incubate at 30˚C or 37˚C depending on the used growth conditions until most of the 
cells have been converted to spheroplasts. 
3. Add cold Buffer A and immediately centrifuge 4000rpm for 10 minutes. Wash two 
additional times with Buffer A 
Buffer A:  1.2M deionized sorbitol (BioRad® AG501-X8 resin) 
 20mM KPO4 pH 7.5 
4. Suspend washed spheroplasts in 0.6M sorbitol, 20mM KMES pH 6, 0.5mM PMSF at 
concentration of 1gr/3ml. Homogenize with and glass/Teflon pestle and overhead 
stirrer (Wheaton Science Products) 
5. Centrifuge 3000rpm for 5 minutes to pellet debries. Collect the supernatant and 
centrifuge 12000rpm for 10 minutes to sediment mitochondria. The supernatant is the 
post mitochondrial fraction (PMS) and represent the cytosolic component 
6. Suspend mitochondria briefly with plastic sticks in 0.6M sorbitol, 20mM KMES pH 6 
(1ml/g of starting cells wet weight) in eppendorf tubes. Centrifuge at 3000rpm for 5 
minutes to pellet broken mitochondria 
7. Collect supernatant and centrifuge at 12000rpm for 10 minutes. Suspend 
mitochondrial pellet in 0.6M sorbitol, 20mM KMES (100 µl/g of starting cells wet 
weight) and dilute with 20ml of 0.6M sorbitol, 20mM HEPES pH 7.4 (1ml/g of starting 
cells wet weight). Centrifuge 12000rpm for 10 minutes. 
8. Suspend mitochondrial pellet in 0.6M sorbitol, 20mM HEPES accordingly to the pellet 
dimension. Mitochondria can be stored at -80˚C. 
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Quantification of proteins with Bradford method 
Protein concentration was determined with Bradford method (Bradford, 1976)The “BioRad 
Protein Assay” commercial kit was utilized according to the manufacturer’s instructions. 
 
Succinate Dehydrogenase (SQDR) enzymatic activity 
This assay measures the rate of reduction of an artificial electron acceptor as 
dichlorophenolindophenol (DCPIP) by complex II as modified by Kim and Beattie, 1973. 
Solutions needed:   100 mM K-phosphate pH 7.8 (30°C) 
     10 mM succinate pH 7.4 
     2.5 mM phenazyne methosulfate (PMS) 
     0,15 mM DCPIP 
     100 mM NaN3 
The SDH activity was recorded at 600nm. 
Specific Activity: SQDR activity was calculated with ε of 21 and the following formula 
(ΔOD*ε/min mg). 
 
Cytochrome c oxidase (COX) enzymatic activity 
This assay measures the rate of cytochrome c oxidation by complex IV in yeast as 
described by Warthon and Tzagaloff, 1967. 
Solutions needed:   10mM K-phosphate pH 7 
     80 µM cytochrome c 
     1 mg/ml BSA (in EDTA 10 mM, pH 7.4) 
COX activity was recorded at 550 nm. 
Specific activity: COX activity is calculated with cytochrome c ε of 21 and the following 
formula (ΔOD*ε/min mg). 
 
Mitochondrial Protein Localization 
Based on Glick procedure 
Prepare mitochondria with intact outer membrane as previously described. 
1. Centrifuge 10000rpm, 10 minutes 4˚C to pellet mitochondria. Set up two different 
tubes with 250µg of total proteins 
2. Wash sample 1 and 2 with 0.6M sorbitol, 20mM HEPES pH 7.4 
3. Set up the following conditions: 
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 1 2 
Mitochondria 250µg 250µg 
0.6M sorbitol, 
HEPES 20 mM 
pH 7.4 
250µl 250µl 
Proteinase K 
(1mg/ml) 
- 5µl 
 
4. Incubate samples on ice for 60 minutes 
5. Add 5µl of 0.1M PMSF to stop reaction of Proteinase K 
6. Centrifuge 15300 rpm, 22 minutes 4˚C. Remove and keep supernatants 
7. Pellet is resuspended in 0.1ml of 0.6M sorbitol, 20mM HEPES pH 7.4 
8. Centrifuge 14000rpm, 5 minutes 4˚C 
9. Dissolve pellets in 100µl of 1X SDS-page loading buffer (LB) and add 2µl of 0.1M 
PMSF 
10. Load 20 in 15% SDS-page and perform western against different mitochondrial 
proteins. Ideally use a control for each mitochondrial compartment  
 
Solubilization of mitochondrial proteins 
To solubilize mitochondrial tagged proteins (for following biochemical characterization) 
different extracting conditions were tested to find the mildest one. The following test 
protocol was used: 
1. Pellet 0.25 mg of total mitochondrial proteins centrifuging 10000rpm 4˚C 
2. Discard supernatant and resuspend in 25µl of Extraction buffer 
Extraction buffer:  20mM HEPES 
   0.5mM PMSF 
   + detergent (digitonin, laurylmaltoside) 
   + salt (NaCl) 
   water to 100µl 
3. Incubate 10 min on ice 
4. Centrifuge 15300 rpm, 30 minutes 4˚C 
5. Transfer 25 µl of supernatant (+5 µl H2O) in a new tube and add 10 µl of LB4X 
6. Wash the pellet twice with 10mM HEPES without resuspending 
7. Resuspend pellet in 40µl of LB1X 
106 
 
Equivalent µg from pellet and supernatant are loaded in SDS page to evaluate the 
extraction efficiency for protein of interest.  
 
Affinity purification analyses with Ni-NTA 
For affinity purification analyses a Ni-NTA agarose (Qiagen) affinity matrix was used, 
consisting of nickel-nitrilotriacetic acid coupled to Sepharose beads. 
General protocol can be briefly summarized as follows. 
Use 60µl of resin for 2 mg of mitochondrial proteins, solubilized with the opportune 
extraction buffer supplemented with 1/10 vol Complete Protease Inhibitor Cocktail 
(Roche) and 1/10 vol PMSF 10mM  . 
Solutions needed: 
Buffer A:  50mM Na-Phospate pH 8.0 
  15mM Imidazole 
  50mM NaCl 
  15% glycerol 
1. Pellet Ni-NTA beads 1000 rpm 1min 4˚C 
2. Wash three times with 10 volumes of Buffer A  
3. Add supernatant from mitochondrial protein solubilization (2-4mg) 
4. Incubate o/n 4˚C in gently rotation 
5. Centrifuge 1min 1000 g 4°C 
6. Recover the supernatant  (Flow Through fraction) and keep the pellet 
7. Wash 5 times with 1.5ml of Buffer A 
8. Eluition with SDS loading buffer 1X. 
Volumes and timing have to be optimized. A standard condition can be 20-30 minutes in 
gently rotation at room temperature. Load equivalent quantities of FT and ELUATE 
fractions on SDS-page along with extraction control. 
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